

AD

(Leave blank)

Award Number: **W81HWH-10-1-0469**

TITLE:

**Genetic Evaluation for the Scoliosis Gene(s) in Patients with
Neurofibromatosis 1 and Scoliosis**

PRINCIPAL INVESTIGATOR:

David W. Polly, Jr., MD

CONTRACTING ORGANIZATION:

**UNIVERSITY OF MINNESOTA
Minneapolis, MN 55455-2009**

REPORT DATE:

August 2013

TYPE OF REPORT:

Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

✓ Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) August 2013		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 August 2012 to 31 July 2013	
4. TITLE AND SUBTITLE Genetic Evaluation for the Scoliosis Gene(s) in Patients with Neurofibromatosis 1 and Scoliosis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81HWH-10-F-0469	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) David. W. Polly Jr., MD Christopher L. Moertel, MD Charles G.T. Ledonio, MD				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Minnesota Minneapolis, MN 55455-2009				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Dystrophic or non-dystrophic scoliosis is one of most common skeletal manifestations of Neurofibromatosis type 1. Dystrophic scoliosis has a more progressive and debilitating course than non-dystrophic scoliosis thus requiring in most cases surgical intervention. Experts have recommended early intervention for better outcomes but tools for early detection of dystrophic scoliosis have not been developed. The goal of this study is to develop validated radiographic and genetic tools for early detection of dystrophic or non-dystrophic scoliosis. Early detection will allow physicians to provide more timely interventions and consequently improve outcomes and overall clinical management in patients with Neurofibromatosis type 1. Early detection may also lessen the number of imaging modalities such as radiographs and MRIs, thereby lowering cost of medical management. Work to date has focused on radiographic criteria for dystrophic modulation and validation of this radiographic scoring system. Initial patient recruitment for genetic marker testing has begun.					
15. SUBJECT TERMS Neurofibromatosis type I, Dystrophic scoliosis, Radiographic characteristics					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 38	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	5
Body.....	5
Key Research Accomplishments.....	18
Reportable Outcomes.....	19
Conclusion.....	24
References.....	24
Appendices.....	26

INTRODUCTION

Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder occurring in 1:4000 worldwide. Scoliosis is perhaps the most common skeletal problem in patients with NF1 with a prevalence of 10-69%. There are two types: dystrophic and non dystrophic scoliosis. Dystrophic scoliosis appears to have a poorer prognosis. Dystrophic changes develop over time and may not necessarily appear at initial presentation. Therefore the development and validation of a radiographic scheme to classify dystrophic scoliosis is needed to aide in distinguishing dystrophic from non dystrophic scoliosis and allow early detection and intervention and is our first objection. The second objective rests on the fact that NF1 has marked variability of clinical expression. There is evidence that other genes may play a role in NF1 expression. Current research has identified candidate genetic SNP markers that can predict progressive and non-progressive curves in Adolescent Idiopathic Scoliosis (AIS) with a high degree of reliability. If the same genetic markers are present in non-dystrophic scoliosis then this will allow earlier, more accurate prognostication, and perhaps improve treatment. Thus our hypothesis is that NF1 patients with non-dystrophic or dystrophic scoliosis have the same genetic markers as patients with AIS.

Table: NINE RADIOGRAPHIC CHARACTERISTICS OF DYSTROPHIC DEFORMITY IN NF1.

Characteristics	% incidence
Rib penciling	62
Vertebral rotation	51
Posterior vertebral scalloping	31
Vertebral wedging	36
Spindling of transverse processes	31
Anterior vertebral scalloping	31
Widened intervertebral foramina	29
Enlarged intervertebral foramina	25
Lateral vertebral scalloping	13

From Durrani AA, Crawford AH, Choudry SN, et al.

Body

NF 1 patients with scoliosis can present as either non dystrophic or dystrophic scoliosis. Non dystrophic scoliosis behave and evolve similarly to that of AIS patients. Therefore, we hypothesize that:

Neurofibromatosis type 1 patients with non-dystrophic scoliosis have a similar curve progression risk profile markers as patients with Adolescent Idiopathic Scoliosis. Dystrophic scoliosis patients will not have the same curve progression risk profile as AIS.

To test this hypothesis this study was divided into two main phases. Phase 1 involves the development and validation of a radiographic scheme to classify radiographic dystrophic changes in patients with NF1 scoliosis. In phase 2 of the study, this validation scheme will be used to distinguish dystrophic vs. non dystrophic scoliosis patients and correlate that with genetic marker testing.

Phase 1:

The aim of the first phase is to development and validation of a scheme to classify dystrophic changes

in patients with NF 1 scoliosis with the goal of creating a validated clinical radiographic grading scheme for the diagnosis dystrophic scoliosis in NF1 patients.

Hypothesis: Radiographic characteristics of dystrophic deformity described by Crawford and Durrani et. al. will distinguish dystrophic scoliosis from non-dystrophic scoliosis.

A checklist of radiographic findings indicating dystrophic curves has been developed. However this has not been validated to date.^[8] Our team has experience in developing and validating spinal radiographic measures with particular expertise in validation of reliability of scoliosis measurements.^[4,7,11,12,13,18,19,20,21,22,27,28,29,30,31] From these radiographs (and from other example images available from participating surgeons' files) the spectrum of severity of these findings will be selected. For each category a severity scale will be developed. Intra- and inter-observer reliability will then be tested and reported.

Analysis Methods

The general objective of this study is to evaluate the operating characteristics of diagnostic procedures, based on radiographs, for dystrophic scoliosis. We are interested in (1) estimating the reliability of between-observer evaluations, and (2) estimating the sensitivity and specificity of radiography based classification relative to the 'gold standard' of a definitive clinical diagnosis.

Reliability

The primary outcome variable of interest is whether a patient's radiograph indicates dystrophic scoliosis. This is a binary outcome. We will quantify the intra-observer reliability for each assessor, using the agreement between each assessor's first and second readings of a given patient radiography. We will also quantify the inter-observer reliability for both the agreement among experts and the agreement between experts and non-experts, using the kappa measure of agreement.

The sample size for the inter-observer reliability assessment was estimated for two situations of interest:

In the first, we are interested in the level of agreement between two experts. We assume that the proportion of agreement will be approximately 70%, and wish to define the level of agreement within a 95% confidence level margin of error of 10%. That is, if the observed proportion of agreement is 70%, we would want the 95% confidence interval for the true proportion of agreement to be (60%, 80%). This will require a sample size of **81 patient radiographs**.

In the second, we are interested in the level of agreement between an expert and a non-expert. We assume that the proportion of agreement will be approximately 50%, and wish to define the level of agreement within a 95% confidence level margin of error of 10%. This necessitates a sample size of **97 patient radiographs**.

Predictive Ability: Sensitivity and Specificity:

First, we will determine how well each of the nine radiographic characteristics alone predicts dystrophic scoliosis using standard diagnostic test criteria of sensitivity and specificity.

Second, we will assess which combinations of the nine characteristics most accurately and precisely predict dystrophic scoliosis using multiple logistic regression, with the known dystrophic status as the binary outcome and the nine radiographic characteristics as binary predictors. From this we will obtain a composite variable which is predictive of dystrophic scoliosis. We will estimate the sensitivity and specificity of this composite logistic predictor, again using the established clinical diagnosis as the gold standard.

The sample size for assessing the sensitivity and specificity of the composite predictor was estimated

assuming that the test sensitivity and specificity will both be 90% and that we would like the 95% exact binomial confidence intervals for each to be (80%, 98%). This will require a sample size of 75 dystrophic patient radiographs and 75 non-dystrophic patient radiographs.

Phase 1 Tasks:

The estimated time to completion of aim 1 is 1.5 years from the official start of this project (August 1, 2010).

To accomplish aim 1 the following tasks and their status are enumerated below:

- a. Preoperative radiographs of patients with dystrophic and non dystrophic scoliosis will be evaluated. All radiographs in film format will be scanned and converted to digital format. Dr. Ledonio and Dr. Polly will collect and initially evaluate the radiographs.
 - Letters to solicit de-identified whole spine radiographs of NF1 patients with scoliosis were sent to 10 spine surgeons who are members of the SDSG. To date a total of 252 radiographs from 123 cases of dystrophic or non dystrophic scoliosis were screened and evaluated by first Dr. Ledonio then by Dr. Polly. One case was excluded for a total of 122 cases. Of which 83 (68%) were dystrophic and 39 (32%) were non dystrophic scoliosis cases.
- b. A grading scheme for severity of each dystrophic factor will be developed by Dr. Crawford and Dr. Polly (see minutes in appendix).
 - On April 21-22, 2011 experts from Texas Scottish Rite, Cincinnati Children's Hospital and Axial Biotech gathered at the Department of Orthopaedic Surgery, University of Minnesota's special grand rounds event to lecture on their experiences on the treatment Neurofibromatosis type 1 patients with scoliosis. This was followed by a study group meeting to discuss and clarify the definitions for the radiographic characteristics of dystrophic scoliosis. The radiographic characteristics agreed upon were as follows:
 1. Short sharp angular curve
 2. Rib Penciling
 3. Vertebral rotation
 4. Vertebral scalloping
 5. Vertebral Wedging
 6. Spindling of transverse processes
 7. Widened interpedicular distance
 8. Atypical location
- c. This grading scheme was reviewed by Drs. Polly, Crawford, Sucato, and Larson for initial face validity.
 - The following day a sample set of the radiographic cases were graded (as present or not present) using each of the above characteristics followed by a determination of either dystrophic or non dystrophic.
- d. A set of images was sent to several scoliosis surgeons for intra- and inter-observer reliability testing to determine generalized reliability.
 - 122 sets of scoliosis radiographs were sent to 5 spine surgeons for grading.
 - Data were then screened, cleaned and entered into a database (appendix) and sent to the statistician for analysis as described previously. The results are as follows:

Statistical Report

Data Set {Program: Ledonio analysis 2011-06-14.sas.}

Spinal x-rays from 122 patients were evaluated independently by 5 orthopedic surgeons ('readers') on the presence or absence of 8 characteristics (e.g. 'rib penciling') and on whether they would diagnose the patient as dystrophic or not. The five surgeons were not aware of the clinical diagnosis for the patients. The resulting dataset contained 5 observations for each of the 122 x-rays or 610 total observations on 9 variables. {File: Radiographic grading database 6-13-11.xls, received in corrected form from Dr. Ledonio on 6-15-11.}

The 'gold standard' clinical diagnosis for each x-ray, made by the patient's surgeon based on clinical data, physical examination, MRI and CT scans, surgical observations and results, as well as the x-ray data, were provided in a separate file. {File: Key NF1 Scoliosis Films.xls, received from Dr. Ledonio on 6-14-11.}

All statistical analysis was carried out using SAS 9.2.

Results

Proportion Dystrophic

Overall, 363 of the 610 readings (59.5%) were deemed dystrophic ('dys'). For a given reader, the proportion deemed dystrophic ranged from 45.1% to 67.2% as shown in the table below. The differences among readers are statistically significant (Pearson's chi-square test, p-value = 0.0060). If the reader with the lowest proportion (Sucato) is excluded, the differences among readers are no longer significant (p-value = 0.7201).

Reader	Frequency No-dystrophic (percent)	Frequency Yes-dystrophic (percent)	Total
Carreon	47 (38.52)	75 (61.48)	122
Crawford	45 (36.89)	77 (63.11)	122
Larson	40 (32.79)	82 (67.21)	122
Polly	48 (39.34)	74 (60.66)	122
Sucato	67 (54.92)	55 (45.08)	122
Total	247 (40.49)	363 (59.51)	610

The *actual* diagnosis was dystrophic for 83 of the 122 x-rays, or 68%. All of the readers underestimated the proportions that were dystrophic.

Accuracy (Sensitivity and Specificity)

A comparison of the actual diagnosis ('dys_true') to the reader's diagnosis ('dys') for the 610 readings is shown in the table below. For the $83 * 5 = 415$ readings on the 83 x-rays that were truly dystrophic, the readers overall were correct only 74.7% of the time, i.e. their overall sensitivity was 74.7%. Similarly, for the 195 readings on x-rays that were truly non-dystrophic, the readers overall were correct only 72.8% of the time, i.e. their overall specificity was 72.8%. The agreement between the true diagnosis and the overall readers' diagnoses, as assessed using the kappa statistic, is 0.44 or 'fair'.

Note that with a sample size of 122 x-rays, the margin of error for both the sensitivity and specificity is about 8%, which is well within the desired precision of 10% used in the original sample size estimate.

Actual diagnosis ↓ (‘dys_true’)	Readers		Total
	No-dystrophic	Yes-dystrophic	
No-dystrophic	142 (72.82%)	53 (27.18%)	195
Yes-dystrophic	105 (25.30%)	310 (74.70%)	415
Total:	247	363	610

Byrt (in *Epidemiology* 1996: 7: 561) proposed these guidelines for interpreting kappa statistics:

0.93 – 1.00	Excellent agreement
0.81 – 0.92	Very good agreement
0.61 – 0.80	Good agreement
0.41 – 0.60	Fair agreement
0.21 – 0.40	Slight agreement
0.01 – 0.20	Poor agreement
≤ 0.00	No agreement

The sensitivity, specificity and agreement with the true diagnosis for each reader is shown in the table below. The agreement with the true diagnosis is ‘fair’ for all readers.

Reader	Sensitivity	Specificity	Agreement with true diagnosis (kappa)
<i>OVERALL</i>	74.7 %	72.8 %	0.44
Carreon	77.1	71.8	0.46
Crawford	77.1	66.7	0.42
Larson	83.1	66.7	0.49
Polly	74.7	69.2	0.41
Sucato	61.5	89.7	0.43

Inter-Observer Reliability

The inter-observer reliability was assessed using Fleiss’ kappa measure of agreement, using the MAGREE macro in SAS and double-checked using the `kappam.fleiss` function in the `irr` package in R. The kappa values for the 8 x-ray characteristics, as well as for the dystrophic diagnosis, for the 122 x-rays read by 5 readers, are shown in the table below. The degree of agreement ranges from ‘poor’ for Vertebral scalloping and Widened interpedicular distance to (just barely) ‘good’ for Vertebral wedging.

Characteristic	Variable name	Fleiss’ kappa
Dystrophic diagnosis	Dys	0.612
Vertebral wedging	Wedge	0.619 - max
Vertebral rotation	Rot	0.589
Sharp angular curve	Curve	0.602
Rib penciling	Pencil	0.414
Vertebral scalloping	Scall	0.140 - min
Widened interpedicular distance	Wide	0.182
Atypical location	Loc	0.276
Spindling of transverse processes	Spind	0.424

The rate at which each characteristic was observed in x-rays deemed dystrophic by a given reader and in x-rays deemed non-dystrophic by a given reader is shown in the table below. The association between each characteristic

and dystrophic diagnosis is highly significant (chi-square test, p-value < 0.0001) for all eight characteristics. The characteristics most often observed in x-rays deemed dystrophic were wedge, rot and curve.

Variable Name	Rate observed in all 610 readings	Rate observed in x-rays deemed dystrophic by a given reader	Rate observed in x-rays deemed non-dystrophic by a given reader
Wedge	61.5 %	90.6 %	18.6 %
Rot	61.2	89.3	19.8
Curve	52.5	84.3	5.7
Pencil	42.8	63.1	13.0
Scall	40.7	57.9	15.4
Wide	36.1	54.8	8.5
Loc	22.3	35.0	3.6
Spind	15.1	23.4	2.8

The rates observed in x-rays that truly were dystrophic vs. non-dystrophic are shown in the second table below. The association between each characteristic and true dystrophic diagnosis is highly significant (chi-square test, p-value < 0.0001) for seven of the eight characteristics, and slightly less significant (p-value = 0.0011) for the eighth (spind).

Variable Name	Rate observed in all 610 readings	Rate observed in truly dystrophic x-rays (sensitivity)	Rate observed in truly non-dystrophic x-rays (1 - specificity)
Wedge	61.5 %	75.9 %	30.8 %
Rot	61.2	76.1	29.2
Curve	52.5	65.3	25.1
Pencil	42.8	54.4	18.0
Scall	40.7	46.8	27.7
Wide	36.1	43.9	19.5
Loc	22.3	29.6	6.7
Spind	15.1	18.3	8.2

The inter-observer reliability was investigated further by counting the number of times a given characteristic was said to be present by the five readers. This count ('sum_dys', 'sum_wedge', etc.) varied from 5 if all 5 readers said the characteristic was present, to 0 if all 5 readers said it was not present. The raw data for agreement on each of the 8 characteristics plus the dystrophic classification are given in the Appendix. The summary tables are shown below.

Dystrophic classification ('dys'): Of the 83 truly dystrophic x-rays, 42 (50.6%) were correctly classified as dystrophic by all five readers. Eight (9.6%) were incorrectly classified non-dystrophic by all five readers. There was some degree of disagreement for the remaining 33 (39.8%) dystrophic x-rays. Similarly, of the 39 non-dystrophic x-rays, 22 (56.4%) were classified correctly by all five readers, four (10.3%) were classified incorrectly by all five readers, and there was some disagreement about the remaining 13 (33.3%).

Number of readers saying 'Yes'			Dystrophic		Total
	Dystrophic No	percent	Yes	percent	
0	22	56.41%	8	9.64%	30
1	2	5.13	4	4.82	6
2	5	12.82	6	7.23	11
3	3	7.69	8	9.64	11
4	3	7.69	15	18.07	18
5	4	10.26	42	50.60	46
Total	39	100.00%	83	100.00%	122

Ignoring the true diagnosis, the sum of yes answers for dystrophic diagnosis ranged from 0 (24.6% of readings) to 5 (37.7%) for the 122 x-rays, as shown below.

'dys' sum_yes	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0	30	24.59%	30	24.59%
1	6	4.92	36	29.51
2	11	9.02	47	38.52
3	11	9.02	58	47.54
4	18	14.75	76	62.30
5	46	37.70	122	100.00

Vertebral wedging ('wedge'):

dys_true	sum_wedge						
Frequency, Row Pct	0	1	2	3	4	5	Total
N	18	7	3	2	4	5	39
	46.15	17.95	7.69	5.13	10.26	12.82	
Y	9	1	8	7	13	45	83
	10.84	1.20	9.64	8.43	15.66	54.22	
Total	27	8	11	9	17	50	122

'wedge' sum_yes	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0	27	22.13	27	22.13
1	8	6.56	35	28.69
2	11	9.02	46	37.70
3	9	7.38	55	45.08
4	17	13.93	72	59.02
5	50	40.98	122	100.00

Vertebral rotation ('rot'):

dys_true	sum_rot						
Frequency, Row Pct	0	1	2	3	4	5	Total
N	18	6	3	5	5	2	39
	46.15	15.38	7.69	12.82	12.82	5.13	
Y	10	2	2	7	21	41	83
	12.05	2.41	2.41	8.43	25.30	49.40	
Total	28	8	5	12	26	43	122

'rot' sum_yes	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0	28	22.95	28	22.95
1	8	6.56	36	29.51
2	5	4.10	41	33.61
3	12	9.84	53	43.44
4	26	21.31	79	64.75
5	43	35.25	122	100.00

Sharp angular curve ('curve'):

dys_true	sum_curve						
Frequency, Row Pct	0	1	2	3	4	5	Total
N	24	2	2	3	6	2	39
	61.54	5.13	5.13	7.69	15.38	5.13	
Y	16	1	7	11	17	31	83
	19.28	1.20	8.43	13.25	20.48	37.35	
Total	40	3	9	14	23	33	122

	'curve' sum_yes	Frequency	Percent	Cumulative Frequency	Cumulative Percent
	0	40	32.79	40	32.79
	1	3	2.46	43	35.25
	2	9	7.38	52	42.62
	3	14	11.48	66	54.10
	4	23	18.85	89	72.95
	5	33	27.05	122	100.00

Rib penciling ('pencil'):

	dys_true	sum_pencil					
	Frequency, Row Pct	0,	1,	2,	3,	4,	5, Total
N	, 20 ,	10 ,	6 ,	1 ,	0 ,	2 ,	39
	, 51.28 ,	25.64 ,	15.38 ,	2.56 ,	0.00 ,	5.13 ,	
Y	, 11 ,	12 ,	16 ,	14 ,	10 ,	20 ,	83
	, 13.25 ,	14.46 ,	19.28 ,	16.87 ,	12.05 ,	24.10 ,	
Total	31	22	22	15	10	22	122

	'pencil' sum_yes	Frequency	Percent	Cumulative Frequency	Cumulative Percent
	0	31	25.41	31	25.41
	1	22	18.03	53	43.44
	2	22	18.03	75	61.48
	3	15	12.30	90	73.77
	4	10	8.20	100	81.97
	5	22	18.03	122	100.00

Vertebral scalloping ('scall'):

	dys_true	sum_scall					
	Frequency, Row Pct	0,	1,	2,	3,	4,	5, Total
N	, 5 ,	24 ,	5 ,	2 ,	1 ,	2 ,	39
	, 12.82 ,	61.54 ,	12.82 ,	5.13 ,	2.56 ,	5.13 ,	
Y	, 4 ,	22 ,	24 ,	16 ,	9 ,	8 ,	83
	, 4.82 ,	26.51 ,	28.92 ,	19.28 ,	10.84 ,	9.64 ,	
Total	9	46	29	18	10	10	122

	'scall' sum_yes	Frequency	Percent	Cumulative Frequency	Cumulative Percent
	0	9	7.38	9	7.38
	1	46	37.70	55	45.08
	2	29	23.77	84	68.85
	3	18	14.75	102	83.61
	4	10	8.20	112	91.80
	5	10	8.20	122	100.00

Widened interpedicular distance ('wide'):

dys_true		sum_wide						
Frequency, Row Pct	,	0,	1,	2,	3,	4,	5,	Total
N	,	16	15	3	3	2	0	39
	,	41.03	38.46	7.69	7.69	5.13	0.00	
Y	,	9	16	29	15	7	7	83
	,	10.84	19.28	34.94	18.07	8.43	8.43	
Total		25	31	32	18	9	7	122

'wide' sum_yes	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0	25	20.49	25	20.49
1	31	25.41	56	45.90
2	32	26.23	88	72.13
3	18	14.75	106	86.89
4	9	7.38	115	94.26
5	7	5.74	122	100.00

Atypical location ('loc'):

dys_true		sum_loc						
Frequency, Row Pct	,	0,	1,	2,	3,	4,	5,	Total
N	,	30	7	0	2	0	0	39
	,	76.92	17.95	0.00	5.13	0.00	0.00	
Y	,	28	18	18	9	8	2	83
	,	33.73	21.69	21.69	10.84	9.64	2.41	
Total		58	25	18	11	8	2	122

'loc' sum_yes	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0	58	47.54	58	47.54
1	25	20.49	83	68.03
2	18	14.75	101	82.79
3	11	9.02	112	91.80
4	8	6.56	120	98.36
5	2	1.64	122	100.00

Spindling of transverse processes ('spind'):

dys_true		sum_spind						
Frequency, Row Pct	,	0,	1,	2,	3,	4,	5,	Total
N	,	31	4	2	1	0	1	39
	,	79.49	10.26	5.13	2.56	0.00	2.56	
Y	,	52	8	10	7	3	3	83
	,	62.65	9.64	12.05	8.43	3.61	3.61	
Total		83	12	12	8	3	4	122

'spind' sum_yes	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0	83	68.03	83	68.03
1	12	9.84	95	77.87
2	12	9.84	107	87.70
3	8	6.56	115	94.26
4	3	2.46	118	96.72
5	4	3.28	122	100.00

Logistic regression

Logistic regression was carried out in order to determine which combination of x-ray characteristics was best able (despite the lack of agreement among readers) to predict true dystrophic status for the N=610 readings. The log odds of an x-ray being truly dystrophic were modeled as a function of the eight x-ray characteristics listed above (coded as 1 if present and -1 if not). No higher order terms or interaction terms were considered.

When backward elimination was used to determine which characteristics were most predictive of true dystrophic status, four characteristics (spind, curve, wide and scall) were eliminated since they were not significant at the alpha = 0.05 level (table below).

Summary of Backward Elimination

Step	Effect Removed	DF	Number In	Wald Chi-Square	Pr > ChiSq
1	spind	1	7	0.0360	0.8495
2	curve	1	6	0.0631	0.8016
3	wide	1	5	0.3541	0.5518
4	scall	1	4	0.6924	0.4053

The modeling results indicate that four characteristics, pencil, rot, wedge and loc, are strongly associated with true dystrophic status. The odds of an x-ray being truly dystrophic are 2.43 times higher when the reader saw rib penciling ('pencil') than when the reader did not. Similarly the odds of an x-ray being truly dystrophic are 2.97 times higher if the reader saw vertebral rotation ('rot'), 2.37 times higher if he saw vertebral wedging ('wedge') and 3.00 times high if he saw atypical location ('loc'). If the reader saw all four of these characteristics at once, the odds of that x-ray being truly dystrophic are 51 times higher than if he saw none of the four characteristics.

Analysis of Maximum Likelihood Estimates

Parameter	DF	Estimate	Standard Error	Wald Chi-Square	Pr > ChiSq
Intercept	1	1.1940	0.1708	48.8548	<.0001
pencil Y	1	0.4445	0.1216	13.3687	0.0003
rot Y	1	0.5455	0.1212	20.2577	<.0001
wedge Y	1	0.4310	0.1218	12.5297	0.0004
loc Y	1	0.5488	0.1650	11.0591	0.0009

Odds Ratio Estimates

Effect	Point Estimate	95% Wald Confidence Limits
pencil Y vs N	2.432	1.510 3.917
rot Y vs N	2.977	1.851 4.788
wedge Y vs N	2.368	1.469 3.816
loc Y vs N	2.997	1.569 5.722


When forward selection was used, the results were identical with the results for backward selection (table below); this gives increased confidence that the chosen four characteristics are likely the ones that really matter. Stepwise selection was also tried, with identical results.

Summary of Forward Selection

Step	Effect Entered	DF	Number In	Score Chi-Square	Pr > ChiSq
1	rot	1	1	122.9014	<.0001
2	wedge	1	2	28.5889	<.0001
3	pencil	1	3	14.1359	0.0002
4	loc	1	4	11.8334	0.0006

The model-predicted probability of being dystrophic (blue dots) and the actual probability of being dystrophic (red squares) are given in the table and figure below, as a function of a created variable called 'sum4_pattern4'. The first digit of this variable gives the number of the four characteristics in the model which were observed in a given reading. The remaining four digits of this variable are NNNN if all four characteristics (rot, wedge, pencil and loc, in that order) were not observed by the reader, YNNN if the reader observed only rot and not the other three characteristics, and so on. So if a reader saw rot and pencil, the pattern variable would be 2YNNY.

Obs	sum4_ pattern4	Pred_ Percent_ Dys	Actual_ Percent_ Dys
1	0NNNN	31.5248	34.194
2	1NNNY	57.9768	66.667
3	1NNYN	52.8273	52.941
4	1NYNN	52.1564	50.000
5	1YNNN	57.8183	43.333
6	2NNYY	77.0428	50.000
7	2NYYN	76.5635	25.000
8	2NYYN	72.6159	64.286
9	2YNNY	80.4213	75.000
10	2YNYN	76.9276	80.000
11	2YYNN	76.4467	79.167
12	3NYYY	88.8225	85.714
13	3YNNY	90.9022	100.000
14	3YYNY	90.6772	92.857
15	3YYYY	88.7578	88.489
16	4YYYY	95.9447	98.462



Keep in mind that since each x-ray was read five times, and the five readings did not always agree, a given x-ray may contribute to as many as five different patterns.

The model predictions are reasonably close to the actual values. The model predicts that the probability of an x-ray being truly dystrophic is about 31% if the reader saw none of these four characteristics. The probability rises to about 52-58% if the reader saw one of the four characteristics, to about 72-80% if he saw two of them, to about 88-91% if he saw three of them, and to about 96% if he saw all four of them.

Phase 2

The aim of phase 2 of this study is to perform genetic testing on patients with NF 1 who have had clinical treatment for scoliosis.

Hypothesis: The curve progression risk profile for AIS is also found in non-dystrophic but not in dystrophic scoliosis.

The samples in Aim #1 would be the same samples with non-dystrophic scoliosis with a known outcome at skeletal maturity. These samples will be collected retrospectively according to inclusion and exclusion criteria and final outcome. The statistical analysis would be a simple comparison to see whether the sensitivity of the genetic panel in NF1 patients with scoliosis is similar to the AIS study (85%). The study will test NF1 patients, in both dystrophic and non dystrophic categories, that have been treated with fusion surgery.

Genotyping:

Genetic testing will be done at Axial Biotech. DNA collection and genotyping of the sample cohorts with 53 single-nucleotide polymorphism (SNP) markers associated with progression to a surgical curve in AIS patients (Table 5). The results of the SNP marker analysis are represented as a numerical score and as high, intermediate or low risk genetic profile for curve progression. The validated scheme in Aim 1 will be used to classify the scoliosis as dystrophic or non dystrophic.

Specifically, two millimeters of saliva is collected in an DNA Genotek (Ottawa, Canada), Oragene OG-300 sample collection kit. DNA samples are extracted from the saliva using MagNA Pure Compact magnetic bead extraction protocols (Roche Applied Sciences, Indianapolis, IN). Genotypes are determined using 53 Taqman™ assays (Applied Biosystems, Inc., Foster City, CA) designed to detect the each SNP. The Taqman assay is an allele discrimination assay using PCR amplification and a pair of fluorescent dye detectors that target each SNP. One fluorescent dye is attached to the detector that is a perfect match to the first allele (e.g. an “A” nucleotide) and a different fluorescent dye is attached to the detector that is a perfect match to the second allele (e.g. a “C” nucleotide). During PCR, the polymerase will release the fluorescent probe into solution where it is detected using endpoint analysis in an Applied Biosystems 7900HT Real-Time instrument. Genotypes are determined using Applied Biosystems automated Taqman genotyping software, SDS v2.3. After genotypes are determined the risk progression score is determined for each patient using a logistic regression algorithm determined during the discovery and validation phases of the original research. All samples and scores are tracked in a Laboratory Information Management System. Testing is done in Axial Biotech’s CLIA/CAP accredited laboratory.

Analysis Methods and Assessment of Data:

The objective of Aim 2 is to evaluate the clinical utility of a set of genetic markers in NF1 patients that have been treated clinically. These genetic markers have previously been validated as markers associated with the development of surgical curves (> 40 degree Cobb angle in a growing spine) in adolescent idiopathic scoliosis patients. This study will attempt to confirm, in NF1 surgical patients with non-dystrophic scoliosis, the 85% sensitivity observed in surgical adolescent scoliosis patients.

Sample Size Determination:

Two cohorts will be collected, NF1 patients with dystrophic scoliosis that have been treated clinically and NF1 patients with non-dystrophic scoliosis that have been treated clinically. A sample size of at least 100 patients is required to evaluate the sensitivity (lower 95% CI = between 0.70 to 0.75). In anticipation of enrollment drop outs we are approved to recruit 140 subjects to meet sample size requirement of 100 patients.

Sample Size Determination

Expected Sensitivity	<u>Minimum Acceptable 95% Lower Confidence Limit</u> Sample size						
	0.50	0.55	0.60	0.65	0.70	0.75	0.80
0.85	18	26	33	52	85	176	624

Phase 2 tasks:

The estimated time to completion of aim 2 is 1.5 years after the end of phase 1.

To accomplish aim 2 the following tasks and their status are enumerated below:

Task 2: Identification, recruitment and informed consent acquisition of 200 NF1 patients with scoliosis from SDSG and NF support groups.

- a. Once identified, letters of invitation to participate in this study together with informed consent form was

sent by Dr. Polly and his staff. The research coordinator at the University of Minnesota will keep track of study participants. Dr. Christopher Moertel was a resource for patient recruitment along with the Spinal Deformity Study Group and Children's Tumor Foundation. Also included was Cincinnati Children's Hospital with Dr. Alvin Crawford as the site-PI.

- During the course of the study approximately 1200 letters were sent to patients diagnosed with NF type 1. Of these 54 qualify for the study. 10 were excluded because they did not meet inclusion criteria. In addition, upon IRB approval we utilized several different social media venues by advertising our study on ClinicalTrials.gov, Children's Tumor Foundation, and The Littlest Tumor Foundation. Midwest Society. Expanding our efforts in this manner allowed us to recruit 11 additional individuals and additional 30 expressing interest. Currently we are awaiting consent letters and samples of 10 additional individuals. Additionally, our collaboration with University of Utah was also used to enroll 19 additional individuals in our study. We have plans to expand our recruitment efforts to other organizations and create presence at events organized by different NF1 foundations. As our study was approved for no cost extension, we will utilize new recruitment methods and increase our efforts in order to reach a proposed 100 study participants.
 - At this point a total of 47 subjects have consented and were enrolled in phase 2 of this study. Their samples are processed by Affiliated Genetics, a company formerly known as Axial Biotech (name change occurred recently).
- b. Once informed consent is obtained participants are referred to Affiliated Genetics (formerly Axial Biotech). Affiliated Genetics sends the participants a buccal swab kits with a self-addressed stamped envelope. Some participants would receive buccal swab kits along with their informed consent in order to expedite the process and decrease a burden on patient by decreasing the amount of involvement necessary to participate in the study. This action has allowed increasing recruitment efforts.
- c. Participants will be asked to swab the inside of their cheeks and to collect DNA sample and mail them back to Affiliated Genetics for genetic testing. They will be guided by written instructions telephone instructions and/or internet video instruction.

Task 3: Perform genetic testing on patients with NF 1 who have had clinical treatment for scoliosis at Affiliated Genetics with Drs. Ogilvie and Ward. (2nd – 3rd years).

- Results of the first 17 swab samples have been reported. Additionally, 30 samples are pending processing by Affiliated Genetics.

Task 4: Preparation of reports, analysis of data and preparation of manuscript (year 4.)

KEY RESEARCH ACCOMPLISHMENTS:


- Collection of a large sample size of de-identified scoliosis radiographs of patients with NF 1 from a multiple centers across the United States.
- Creation of database of radiographic grading for dystrophic scoliosis for 122 sets of scoliosis radiographs 68% of which are dystrophic and 32% are non-dystrophic.
- For 415 readings on the 83 x-rays that were truly dystrophic, the overall sensitivity was 74.7%. Similarly, for the 195 readings on x-rays that were truly non-dystrophic, the overall specificity was 72.8%. The agreement between the true diagnosis and the overall readers' diagnoses, as assessed using the kappa statistic, is 0.44 or 'fair'.
- The degree of agreement for the 8 radiographic characteristics for dystrophic scoliosis ranges from 'poor' for Vertebral scalloping and Widened interpedicular distance to 'good' for Vertebral wedging.

- The association between each characteristic and dystrophic diagnosis is highly significant (chi-square test, p -value < 0.0001) for all eight characteristics. The characteristics most often observed in x-rays deemed dystrophic were vertebral wedging, vertebral rotation and sharp angular curve.
- The modeling results indicate that four characteristics, pencil, rot, wedge and loc, are strongly associated with true dystrophic status. The odds of an x-ray being truly dystrophic are 2.43 times higher when the reader saw rib penciling ('pencil') than when the reader did not. Similarly the odds of an x-ray being truly dystrophic are 2.97 times higher if the reader saw vertebral rotation ('rot'), 2.37 times higher if he saw vertebral wedging ('wedge') and 3.00 times high if he saw atypical location ('loc'). If the reader saw all four of these characteristics at once, the odds of that x-ray being truly dystrophic are 51 times higher than if he saw none of the four characteristics. To put it another way, the model predicts that the probability of an x-ray being truly dystrophic is about 31% if the reader saw none of these four characteristics. The probability rises to about 52-58% if the reader saw one of the four characteristics, to about 72-80% if he saw two of them, to about 88-91% if he saw three of them, and to about 96% if he saw all four of them.

REPORTABLE OUTCOMES:

As a result of phase 1 efforts, four abstracts were accepted as poster presentations at the IMAST and CTF annual meetings. (See appendix)

Poster for CTF annual meeting 2012:



Neurofibromatosis Type I and Scoliosis: A Multicenter Study to Determine Radiographic Predictors of Dystrophic Scoliosis

Moertel, Christopher L.; Loder, Charles Gerald T.; Polley Jr., David W.; Benaroy, Ann M.; Crawford, Alvin H.; Sucato, Daniel J.; Carroon, Leah Y.; Larson, A. Noelle; Stevenson, David A.; Vitale, Michael G.

1. University of Minnesota, Minneapolis, MN; 2. Cincinnati Children's Hospital, Cincinnati, OH; 3. Texas Scottish Rite Hospital for Children, Dallas, TX; 4. Norton Leatherman Spine Center, Louisville, KY; 5. Mayo Clinic, Rochester, MN; 6. University of Utah, Salt Lake City, UT; 7. Columbia University Medical Center, New York, NY

This study was funded by a research grant from: DOD Neurofibromatosis Investigation-Instituted Research Award (# W81XWH-05-1-0488)

INTRODUCTION

Scoliosis in Neurofibromatosis type I: Dystrophic or non-dystrophic?

- Nondystrophic and dystrophic
- Most common osseous defect
- 2% of pts with scoliosis will have NF-1
- 30% of patients with NF-1 have spine disorders
- Dystrophic spine lesions (Crawford 2007, 2007)

Natural History


- Carver et al. JUS 87 1989
 - Treated (n=4) and untreated (n=22) w/ NF-1 scoliosis
 - 75% untreated group had kyphoscoliosis
 - Severe anterior scalloping - progressed 22°/yr
 - All others 7°/yr progression and 8°/yr of kyphosis
- Miles et al. Spine 1994
 - Vertebral subluxation, disc wedging and peripheral vascular dysplasia
 - prognostic factors that predict progression after arthrodesis

Certain radiographic characteristics have been reported to predict dystrophic scoliosis, but their predictive value is not well described. It is unclear which set of radiographic features are most predictive of dystrophic scoliosis and will stand up in a robust statistical model.


This study aims to determine which combination of x-ray characteristics was best able to predict true dystrophic status.

EXAMPLES

Sharp angular curve



Dural ectasia; vertebral scalloping



RESULTS

Logistic regression analysis modeling: backward, forward and stepwise elimination

Modeling indicates that rib penciling; vertebral rotation, vertebral wedging and atypical location are strongly associated with dystrophic status (p -values < 0.001). The other four characteristics were not significantly associated with dystrophic status, given the presence of the first four characteristics in the model (p -values > 0.4).

- Spinning of transverse processes
- Short sharp angular curve
- Widened interpedicular space
- Vertebral scalloping
- $p > 0.05$

Strong predictors of dystrophic scoliosis

- Rib penciling
- Vertebral rotation
- Vertebral wedging
- Atypical location
- $p < 0.05$

The odds of an x-ray being dystrophic were 2.43 times higher when rib penciling was present; vertebral rotation - 2.97, vertebral wedging - 2.37, & atypical location 3.00

If all 4 characteristics patterns were present there would be a 51 times higher risk of dystrophic curve pattern.

Model summary

- The model predicts that the probability of an x-ray being truly dystrophic is about 31% if the reader saw none of these four characteristics.
- The probability rises to about 52-58% if the reader saw one of the four characteristics, to about 72-80% if he saw two of them, to about 88-91% if he saw three of them, and to about 96% if he saw all four of them.

METHODOLOGY

Study Design:

Scoliosis radiographs of 122 NF1 patients from multiple institutions were graded by NF-experienced spine surgeons as dystrophic or non-dystrophic based on eight radiographic characteristics: vertebral wedging, vertebral rotation, sharp angular curve, rib penciling, vertebral scalloping, widened interpedicular distance, atypical location, and spinning of transverse processes. Of the 122 cases, 83 (68%) were classified by the contributing institution as dystrophic and 39 (32%) were classified as non-dystrophic. Logistic regression was used to model the odds of an x-ray being dystrophic as a function of the 8 radiographic characteristics. Backward elimination, forward elimination, and stepwise selection were used to determine which characteristics were most predictive of dystrophic status.

Eight Radiographic characteristics of Dystrophic scoliosis

- Vertebral wedging
- Vertebral rotation
- Sharp angular curve
- Rib penciling
- Vertebral scalloping
- Widened interpedicular distance
- Atypical location
- Spinning of transverse processes

The 'gold standard' clinical diagnosis for each x-ray, made by the patient's surgeon based on clinical data

Combination of Hx, PE, MRI and CT scans, surgical observations and results.

RESULTS

The actual diagnosis was dystrophic for 83 of the 122 x-rays, or 68%, and 39(32%) were non-dystrophic.

Readers underestimated the proportion that were dystrophic.

For a given reader, the proportion deemed dystrophic ranged from 45.1% to 87.2% as shown in the table below. The differences among readers are statistically significant (Pearson's chi-square test, p -value = 0.0006). If the reader with the lowest proportion (33%) is excluded, the difference among readers are no longer significant (p -value = 0.7291).

Reader	Frequency Non-dystrophic (n=39)	Frequency Dystrophic (n=83)
1	47	25
2	43	27
3	42	42
4	42	42
5	42	42
6	42	42
7	42	42
8	42	42
9	42	42
10	42	42
11	42	42
12	42	42
13	42	42
14	42	42
15	42	42
16	42	42
17	42	42
18	42	42
19	42	42
20	42	42
21	42	42
22	42	42
23	42	42
24	42	42
25	42	42
26	42	42
27	42	42
28	42	42
29	42	42
30	42	42
31	42	42
32	42	42
33	42	42
34	42	42
35	42	42
36	42	42
37	42	42
38	42	42
39	42	42
40	42	42
41	42	42
42	42	42
43	42	42
44	42	42
45	42	42
46	42	42
47	42	42
48	42	42
49	42	42
50	42	42
51	42	42
52	42	42
53	42	42
54	42	42
55	42	42
56	42	42
57	42	42
58	42	42
59	42	42
60	42	42
61	42	42
62	42	42
63	42	42
64	42	42
65	42	42
66	42	42
67	42	42
68	42	42
69	42	42
70	42	42
71	42	42
72	42	42
73	42	42
74	42	42
75	42	42
76	42	42
77	42	42
78	42	42
79	42	42
80	42	42
81	42	42
82	42	42
83	42	42
84	42	42
85	42	42
86	42	42
87	42	42
88	42	42
89	42	42
90	42	42
91	42	42
92	42	42
93	42	42
94	42	42
95	42	42
96	42	42
97	42	42
98	42	42
99	42	42
100	42	42
101	42	42
102	42	42
103	42	42
104	42	42
105	42	42
106	42	42
107	42	42
108	42	42
109	42	42
110	42	42
111	42	42
112	42	42
113	42	42
114	42	42
115	42	42
116	42	42
117	42	42
118	42	42
119	42	42
120	42	42
121	42	42
122	42	42

Discussion: Dystrophic Modulation

- Current et al. Spine 2000
 - Modulation occurred 65% of patients
 - Modulation occurred in 51% of patients scoliosis presented before 7 years and 20% after 7 years
 - Rib penciling only factor influenced progression
 - Progression rate: scoliosis 12° and kyphosis 8°
- Dystrophic modulation may explain underestimation of dystrophic diagnosis by 5 readers.

CONCLUSION

Only four of the 8 classic radiographic findings of dystrophic scoliosis are most predictive. Further research to predict dystrophic curve patterns should focus on these radiographic markers.

19

Abstract #1

TITLE: Neurofibromatosis type I with Dystrophic Scoliosis: A Multicenter Inter-observer Reliability Study of Radiographic Characteristics

AUTHORS (LAST NAME, FIRST NAME):

Ledonio, Charles Gerald T.1; Polly, David W.1; Brearley, Ann M.1; Crawford, Alvin H.2; Sucato, Daniel J.3; Carreon, Leah Y.4; Larson, A. Noelle5; Stevenson, David6; Vitale, Michael G.7; Moertel, Christopher L.1

INSTITUTIONS (ALL):

1. University of Minnesota, Minneapolis, MN, United States.
2. Cincinnati Children's Hospital, Cincinnati, OH, United States.
3. Texas Scottish Rite Hospital for Children, Dallas, TX, United States.
4. Norton Leatherman Spine Center, Louisville, KY, United States.
5. Mayo Clinic, Rochester, MN, United States.
6. University of Utah, Salt Lake City, UT, United States.
7. Columbia University Medical Center, New York, NY, United States.

ABSTRACT BODY:

Summary (80 words max): This multicenter radiographic assessment study has shown that there is good reliability to detect dystrophic scoliosis in NF1 patients by assessing radiographic characteristics of dystrophic modulation.

Introduction: Scoliosis in patients with Neurofibromatosis type I (NF1) can manifest as dystrophic or non-dystrophic. In contrast to nondystrophic, dystrophic scoliosis is rapidly progressive making treatment challenging. 8 radiographic characteristics have been reported to predict dystrophic scoliosis, but the inter-observer reliability is not well described. Rating systems should have high inter-rater reliability to be generalizable. Careful validation of these predictive factors may facilitate early detection and timely treatment intervention to improve outcomes. The purpose of this study is to assess the inter-observer reliability of 8 radiographic characteristics of dystrophic modulation in NF1.

Methods: Scoliosis xrays of 122 NF1 patients from multiple institutions across the United States were graded by 5 spine surgeons as dystrophic or non-dystrophic, based on 8 radiographic characteristics of dystrophic modulation: wedging, rotation, sharp angular curve, rib penciling, scalloping, widened interpedicular distance, atypical location, and spindling transverse processes. The curves were classified by each submitting institution as dystrophic or non-dystrophic. Inter-observer reliability analysis was performed using Fleiss' kappa.

Results: Of the 122 cases, 83(68%) were classified by the contributing institution as dystrophic and 39(32%) were classified as non-dystrophic. The agreement beyond chance among the 5 readers for the overall dystrophic diagnosis was 0.61(good). The agreement beyond chance for each radiographic characteristic ranges from 0.62 for wedging to 0.14 (poor) for scalloping(Table 1). For dystrophic diagnosis, all 5 readers agreed that a case was dystrophic in 46 of 122 cases, and non-dystrophic in 30 of 122 cases, but there was some disagreement in 46 cases. For wedging, where the agreement was 'good', the readers completely agreed more than half of the time. In contrast, where the agreement was 'poor', the readers disagreed in nearly all the cases.

Conclusion: Overall dystrophic diagnosis can be reliably assessed by radiographic characteristics. Some radiographic characteristics, such as wedging, can be reliably assessed with good agreement. The agreement on other characteristics, such as scalloping, is poor.

Table 1. Kappa statistics

Characteristic	kappa
Dystrophic diagnosis	0.612
Vertebral wedging	0.619
Sharp angular curve	0.602
Vertebral rotation	0.589
Spindling of transverse processes	0.424
Rib penciling	0.414
Atypical location	0.276
Widened interpedicular distance	0.182
Vertebral scalloping	0.140

Abstract #2

TITLE: Neurofibromatosis type 1 and Dystrophic Scoliosis: A Multicenter Study of Accuracy of Surgeons' Radiographic Assessment

AUTHORS (LAST NAME, FIRST NAME):

Ledonio, Charles Gerald T.1; Polly, David W.1; Brearley, Ann M.1; Larson, A. Noelle5; Sucato, Daniel J.3; Carreon, Leah Y.4; Crawford, Alvin H.2; Stevenson, David6; Vitale, Michael G.7; Moertel, Christopher L.1

INSTITUTIONS (ALL):

1. University of Minnesota, Minneapolis, MN, United States.
2. Cincinnati Children's Hospital, Cincinnati, OH, United States.
3. Texas Scottish Rite Hospital, Dallas, TX, United States.
4. Norton Leatherman Spine Center, Louisville, KY, United States.
5. Mayo Clinic, Rochester, MN, United States.
6. University of Utah, Salt Lake City, UT, United States.
7. Columbia University Medical Center, New York, NY, United States.

ABSTRACT BODY:

Summary (80 words max): Experienced spine surgeons reviewed 122 scoliosis radiographs of NF1 patients and to establish the predictive value of 8 factors classically associated with a dystrophic scoliosis. All 8 factors were significantly associated with dystrophism, some more sensitive or more specific than others.

Introduction: Scoliosis in NF1 patients can manifest as dystrophic or non-dystrophic. Early detection and subsequent intervention may provide better outcomes. Certain radiographic characteristics are associated with dystrophism but their predictive value has not been well-described. This study aims to determine the accuracy of radiographic assessment of dystrophic modulation in NF1 patients with scoliosis.

Methods: Scoliosis radiographs of 122 NF1 patients from multiple institutions were graded by 5 spine surgeons as dystrophic or non-dystrophic based on 8 radiographic characteristics: wedging, rotation, short sharp angular curve, rib penciling, scalloping, wide interpedicular distance, atypical location, and transverse processes spindling. Of 122 cases, 83(68%) were classified by contributing institution as dystrophic and 39(32%) as non-dystrophic(used as reference standard). Sensitivity and specificity were calculated for the overall assessment and for each characteristic. The association between each characteristic and dystrophic scoliosis was tested using chi-square and quantified as a relative risk (RR).

Results: For the overall assessment, the readers concurred with the assessment of dystrophic scoliosis with a sensitivity of 75% (310/415reads). Similarly, the readers correctly assessed non-dystrophic scoliosis for specificity of 73%(142/195). Positive predictive value 85% and negative predictive value was 57%. Among readers, the sensitivity ranged from 61% to 83% and the specificity from 67% to 90%. For the 8 radiographic characteristics individually, sensitivity ranges from 18% for spindling to 76% for rotation, and the specificity ranges from 69% for wedging to 93% for atypical location. All 8 characteristics are strongly associated with dystrophic scoliosis ($p<0.002$). The association is strongest for atypical location ($RR=4.45$) and weakest, (still significant) for scalloping ($RR=1.9$).

Conclusion: 8 radiographic characteristics were significantly associated with dystrophic modulation in NF1 patients with scoliosis. Wedging and rotation were most sensitive, atypical location and transverse processes spindling were most specific. On balance, atypical location and rib penciling had the strongest association with dystrophic scoliosis.

Table 1

Characteristic	Sensitivity	Specificity	Relative Risk* (95% CI)
Vertebral rotation	76.1 %	70.8 %	2.60 (2.08 – 3.26)
Vertebral wedging	75.9	69.2	2.47 (1.98 – 3.07)
Sharp angular curve	65.3	74.9	2.60 (2.02 – 3.34)
Rib penciling	54.4	82.0	3.03 (2.22 – 4.15)
Vertebral scalloping	46.8	72.3	1.69 (1.32 – 2.17)
Widened interpedicular distance	43.9	80.5	2.25 (1.66 – 3.05)
Atypical location	29.6	93.3	4.45 (2.58 – 7.67)
Spindling of transverse processes	18.3	91.8	2.23 (1.34 – 3.72)

*Risk of a rater seeing the indicated characteristic in dystrophic x-rays vs. in non-dystrophic x-rays.

Abstract #3

TITLE: Neurofibromatosis Type I and Scoliosis: A Multicenter Study to Determine

Radiographic Predictors of Dystrophic Scoliosis

AUTHORS (LAST NAME, FIRST NAME):

Ledonio, Charles Gerald T.1; Polly, David W.1; Brearley, Ann M.1; Larson, A. Noelle3; Sucato, Daniel J.2; Crawford, Alvin H.4; Carreon, Leah Y.5; Stevenson, David6; Vitale, Michael G.7; Moertel, Christopher L.1

INSTITUTIONS (ALL):

1. University of Minnesota, Minneapolis, MN, United States.
2. Texas Scottish Rite Hospital for Children, Dallas, TX, United States.
3. Mayo Clinic, Rochester, MN, United States.
4. Cincinnati Children's Hospital, Cincinnati, OH, United States.
5. Norton Leatherman Spine Center, Louisville, KY, United States.
6. University of Utah, Salt Lake City, UT, United States.
7. Columbia University Medical Center, New York, NY, United States.

ABSTRACT BODY:

Summary (80 words max): Dystrophic scoliosis in NF1 patients can be best predicted by the following radiographic findings – vertebral wedging, rotation, rib penciling, and atypical curve location. If all four factors are present, there is a 51 times increased risk of a dystrophic curve.

Introduction: Scoliosis in Neurofibromatosis type I (NF1) can manifest as non-dystrophic or dystrophic, which can cause rapid progressive deformity. It is unclear which set of radiographic features are most predictive of dystrophic scoliosis and will stand up in a robust statistical model.

Methods: Scoliosis radiographs of 122 NF1 patients from multiple institutions were graded by five fellowship trained spine surgeons as dystrophic or non-dystrophic based on eight radiographic characteristics: vertebral wedging, vertebral rotation, sharp angular curve, rib penciling, vertebral scalloping, widened interpedicular distance, atypical location, and spindling of transverse processes. Of the 122 cases, 83 (68%) were classified by the contributing institution as dystrophic and 39 (32%) were classified as non-dystrophic. Logistic regression was used to model the odds of an x-ray being dystrophic as a function of the 8 radiographic characteristics. No other predictors, higher order terms or interactions were considered. Backward elimination, forward elimination, and stepwise selection were used to determine which characteristics were most predictive of dystrophic status.

Results: Modeling indicates that rib penciling, vertebral rotation, vertebral wedging and atypical location are strongly associated with dystrophic status (p-values < 0.001). The other four characteristics were not significantly associated with dystrophic status, given the presence of the first four characteristics in the model (p-values > 0.4). The odds of an x-ray being dystrophic were 2.43 times higher when rib penciling was present (Table 1). Similarly, the odds ratio for dystrophic curves were: vertebral rotation – 2.98, vertebral wedging – 2.37, atypical location 3.00. If all 4 characteristics patterns were present there would be a 51 times higher risk of dystrophic curve pattern.

Conclusion: Only four of the 8 classic radiographic findings of dystrophic scoliosis are most predictive. Further research to predict dystrophic curve patterns should focus on these radiographic markers.

Table 1. Odds ration of radiographic characteristics

Characteristic	Odds Ratio (95% CI)
Vertebral rotation	2.98 (1.85 – 4.79)
Vertebral wedging	2.37 (1.47 – 3.82)
Rib penciling	2.43 (1.51 – 3.92)
Atypical location	3.00 (1.57 – 5.72)

Abstract Publications and Presentations:

1. Charles Gerald T. Ledonio, MD; David W. Polly, MD; Ann M. Brearley, PhD; Alvin H. Crawford, MD; Daniel J. Sucato, MD, MS; Leah Y. Carreon, MD,MSc; A. Noelle Larson, MD; David Stevenson; Michael G. Vitale, MD, MPH; Christopher L. Moertel, MD. Neurofibromatosis Type I with Dystrophic Scoliosis: A Multicenter Inter-Observer Reliability Study of Radiographic Characteristics [abstract]. In: 19th International Meeting on Advanced Spine Techniques (IMAST); 2012, July 18-21; Istanbul, TURKEY: IMAST; 2012. Final Program, Abstract nr 534. E-poster
2. Charles Gerald T. Ledonio, MD; David W. Polly, MD; Ann M. Brearley, PhD; A. Noelle Larson, MD; Daniel J. Sucato, MD, MS; Alvin H. Crawford, MD; Leah Y. Carreon, MD,MSc; David Stevenson; Michael G. Vitale, MD, MPH; Christopher L. Moertel, MD. Neurofibromatosis Type I and Scoliosis: A Multicenter Study to Determine Radiographic Predictors of Dystrophic Scoliosis [abstract]. In: 19th International Meeting on Advanced Spine Techniques (IMAST); 2012, July 18-21; Istanbul, TURKEY: IMAST; 2012. Final Program, Abstract nr 545. E-poster
3. Charles Gerald T. Ledonio, MD; David W. Polly, MD; Ann M. Brearley, PhD; A. Noelle Larson, MD; Daniel J. Sucato, MD, MS; Leah Y. Carreon, MD, MSc; Alvin H. Crawford, MD; David Stevenson; Michael G. Vitale, MD, MPH; Christopher L. Moertel, MD. Neurofibromatosis Type 1 and Dystrophic Scoliosis: A Multicenter Study of Accuracy of Surgeons' Radiographic [abstract]. In: 19th International Meeting on Advanced Spine Techniques (IMAST); 2012, July 18-21; Istanbul, TURKEY: IMAST; 2012. Final Program, Abstract nr 549. E-poster
4. Charles Gerald T. Ledonio, MD; David W. Polly, MD; Ann M. Brearley, PhD; A. Noelle Larson, MD; Daniel J. Sucato, MD, MS; Leah Y. Carreon, MD, MSc; Alvin H. Crawford, MD; David Stevenson; Michael G. Vitale, MD, MPH; Christopher L. Moertel, MD. Neurofibromatosis Type 1 and Dystrophic Scoliosis: A Multicenter Study of Accuracy of Surgeons' Radiographic [abstract]. In: 19th International Meeting on Advanced Spine Techniques (IMAST); 2012, July 18-21; Istanbul, TURKEY: IMAST; 2012. Final Program, Abstract nr 549. E-poster
5. David Polly, M.D., Charles Ledonio, M.D., Christopher Moertel, MD Neurofibromatosis Type I and Scoliosis: A Multicenter Study to Determine Radiographic Predictors of Dystrophic Scoliosis [Podium presentation]. In: International Congress on Early Onset Scoliosis and Growing Spine (ICEOS); 2012, November 15-16; Dublin, Ireland.
6. Christopher Moertel, MD; David Polly, M.D; Charles Ledonio, M.D., *Radiographic Assessment Reliability of Dystrophic Modulation in NF1 Patients with Scoliosis* [Podium Presentation]. In: Children's Tumor Foundation, UMN Symposium; Minneapolis, Minnesota (MN), May 16 2012.
7. Ledonio, Charles Gerald T.; Polly, David W.; Brearley, Ann M.; Crawford, Alvin H.; Sucato, Daniel J.; Carreon, Leah Y.; Larson, A. Noelle; Stevenson, David; Vitale, Michael G.; Moertel, Christopher L.

Neurofibromatosis type I with Dystrophic Scoliosis: A Multicenter Inter-observer Reliability Study of Radiographic Characteristics. (Poster# 298) Global Spine Congress, April 4-6, 2013. Hong Kong.

8. Ledonio, Charles Gerald T.; Polly, David W.; Brearley, Ann M.; Crawford, Alvin H.; Sucato, Daniel J.; Carreon, Leah Y.; Larson, A.Noelle; Stevenson, David; Vitale, Michael G.; Moertel, Christopher L. Neurofibromatosis type 1 and Dystrophic Scoliosis: A Multicenter Study of Accuracy of Surgeons' Radiographic Assessment. (Poster# P299) Global Spine Congress, April 4-6, 2013. Hong Kong.
9. Ledonio, Charles Gerald T.; Polly, David W.; Brearley, Ann M.; Crawford, Alvin H.; Sucato, Daniel J.; Carreon, Leah Y.; Larson, A. Noelle; Stevenson, David; Vitale, Michael G.; Moertel, Christopher L. Neurofibromatosis type 1 and Dystrophic Scoliosis: A Multicenter Study of Accuracy of Surgeons' Radiographic Assessment. Poster, NASS Value Award nominee. *North American Spine Society (NASS)* 28th Annual Meeting. October 9-12, 2013. New Orleans, Louisiana.

CONCLUSION:

No conclusions have been made at this juncture. We are approved for no cost extension as we would like to reach our recruitment goal of 100 individuals. Letter of approval is included with this document in the attachments.

REFERENCES:

10. Akbarnia BA, Gabriel KR, Beckman E, Chalk D. Prevalence of scoliosis in Neurofibromatosis. *Spine*. 1992 Aug;17(8 Suppl):S244-8
11. Brooks HL, Azen SP, Gerberg E. et al. (1975): Scoliosis: a prospective epidemiological study. *J Bone Joint Surg Am* 57:968-972.
12. Cummings RJ, Loveless EA, Campbell J, Samelson S, Mazur JM. Interobserver reliability and intraobserver reproducibility of the system of King et al. for the classification of adolescent idiopathic scoliosis. *J Bone Joint Surg Am*. 1998 Aug;80(8):1107-11.
13. Crawford AH, Herrera-Soto J. Scoliosis associated with neurofibromatosis. *Orthop Clin North Am*. 2007 Oct;38(4):553-62
14. Crawford A. H. Pitfalls of spinal deformities associated with neurofibromatosis in children. *Clin Orthop* 1989; 245: 29-42.
15. Dang NR, Moreau MJ, Hill DL, Mahood JK, Raso J. Intra-observer reproducibility and interobserver reliability of the radiographic parameters in the Spinal Deformity Study Group's AIS Radiographic Measurement Manual. *Spine*. 2005 May 1;30(9):1064-9.
16. Durrani AA, Crawford AH, Choudry SN, et al. Modulation of spinal deformities in patients with neurofibromatosis type 1. *Spine* 2000;25:69–75
17. Friedman JM. 1999. The epidemiology of neurofibromatosis type 1. *Am J Med Genet* 89:1-6
18. Easton DF, Ponder MA, Huson SM, Ponder BAJ. 1993. An analysis of variation in expression of neurofibromatosis type 1(NF1): evidence for modifying genes. *Am J Hum Genet* 53:305–313.

19. Gstoettner M, Sekyra K, Walochnik N, Winter P, Wachter R, Bach CM. Inter- and intraobserver reliability assessment of the Cobb angle: manual versus digital measurement tools. *Eur Spine J*. 2007 Oct;16(10):1587-92. Epub 2007 Jun 5.
20. Gupta MC, Wijesekera S, Sossan A, Martin L, Vogel LC, Boakes JL, Lerman JA, McDonald CM, Betz RR. Reliability of radiographic parameters in neuromuscular scoliosis. *Spine*. 2007 Mar 15;32(6):691-5.
21. Kane Wj, MoeJH (1970): A scoliosis-prevalence survey in Minnesota. *Clin Orthop* 69,216-218.
22. Kuklo TR, Potter BK, O'Brien MF, Schroeder TM, Lenke LG, Polly DW, Jr. Reliability Analysis for Digital Adolescent Idiopathic Scoliosis Measurements. *J Spinal Disord Tech* 18:153-159, 2005.
23. Kuklo TR, Potter BK, Polly DW Jr, O'Brien MF, Schroeder TM, Lenke LG. Reliability analysis for manual adolescent idiopathic scoliosis measurements. *Spine*. 2005 Feb 15;30(4):444-54.
24. Lenke LG, Betz RR, Bridwell KH, Clements DH, Harms J, Lowe TG, Shufflebarger HL. Intraobserver and interobserver reliability of the classification of thoracic adolescent idiopathic scoliosis. *J Bone Joint Surg Am*. 1998 Aug;80(8):1097-106.
25. National Institute of Health Consensus Development Conference. NF-1. 1988. p. 172–8.
26. Ogilvie JW, Braun J, Argyle V, Nelson L, Meade M, Ward K. The search for idiopathic scoliosis genes. *Spine*. 2006 Mar 15;31(6):679-81.
27. Ogilvie JW, Ward K, Axial Biotech, Inc. Genetic Profile Predicts Curve Progression in Adolescent Idiopathic Scoliosis. Unpublished, Abstract submitted to Spine Research Society 2008
28. Polly DW Jr, Kilkelly FX, McHale KA, Asplund LM, Mulligan M, Chang AS. Measurement of lumbar lordosis. Evaluation of intraobserver, interobserver, and technique variability. *Spine*. 1996 Jul 1;21(13):1530-5; discussion 1535-6.
29. Pearson TA, Manolio TA. March 19, 2008. How to interpret a genome-wide association study. *JAMA*, 299:11, 1335-1344

APPENDICES

Grading sheet

Name:					Date:					
Instructions: 1) Enter the ID of each radiograph. 2) Write a check mark or "Y" for each characteristic that is present for each radiograph.										
	<u>Xray ID#</u>	<u>Dystrophic Deformity</u>	<u>Sharp angular curve</u>	<u>Rib Penciling</u>	<u>Vertebral Rotation</u>	<u>Vertebral scalloping</u>	<u>Vertebral Wedging</u>	<u>Spindling of transverse processes</u>	<u>Widened interpedicular distance</u>	<u>Atypical location</u>
1										
2										
3										
4										
5										
6										
7										
8										
9										
10										
11										
12										
13										
14										
15										
16										
17										
18										
19										
20										
21										
22										
23										
24										
25										
26										
27										
28										
29										
30										


E-posters


Abstract #1

**Neurofibromatosis type 1 with Dystrophic
Scoliosis: A Multicenter Inter-observer
Reliability Study of Radiographic
Characteristics**

Lindholm, Charles Gwendolyn T¹, Parry, David W¹,
Bromberg, Amy M², Chhabra, Anshu K³, Scully, Daniel J⁴,
Cannon, Leah T⁵, Laitano, A. Heather⁶, Rosenbaum, David
A⁷, Vitek, William J⁸, Morley, Christopher L⁹

¹University of Colorado Denver, Aurora, CO, United States
²University of Colorado Denver, Aurora, CO, United States
³University of Colorado Denver, Aurora, CO, United States
⁴University of Colorado Denver, Aurora, CO, United States
⁵University of Colorado Denver, Aurora, CO, United States
⁶University of Colorado Denver, Aurora, CO, United States
⁷University of Colorado Denver, Aurora, CO, United States
⁸University of Colorado Denver, Aurora, CO, United States
⁹University of Colorado Denver, Aurora, CO, United States





University of Colorado
Denver

E-Poster #224: NP1 & Dysrophic scoliosis: A Multifactorial disorder

1. Location: Meeting Rooms, 2nd Floor, 2nd Hall

2. Date: 29-30 July, 2010

3. Chair: Dr. Thomas K. Heller, MD

4. Co-Chair: Dr. Thomas K. Heller, MD

5. Topic: NP1 & Dysrophic scoliosis

6. Abstracts: 10

7. Abstracts: 10

8. Abstracts: 10

9. Abstracts: 10

10. Abstracts: 10

11. Abstracts: 10

12. Abstracts: 10

13. Abstracts: 10

14. Abstracts: 10

15. Abstracts: 10

16. Abstracts: 10

17. Abstracts: 10

18. Abstracts: 10

19. Abstracts: 10

20. Abstracts: 10

21. Abstracts: 10

22. Abstracts: 10

23. Abstracts: 10

24. Abstracts: 10

25. Abstracts: 10

26. Abstracts: 10

27. Abstracts: 10

28. Abstracts: 10

29. Abstracts: 10

30. Abstracts: 10

31. Abstracts: 10

32. Abstracts: 10

33. Abstracts: 10

34. Abstracts: 10

35. Abstracts: 10

36. Abstracts: 10

37. Abstracts: 10

38. Abstracts: 10

39. Abstracts: 10

40. Abstracts: 10

41. Abstracts: 10

42. Abstracts: 10

43. Abstracts: 10

44. Abstracts: 10

45. Abstracts: 10

46. Abstracts: 10

47. Abstracts: 10

48. Abstracts: 10

49. Abstracts: 10

50. Abstracts: 10

51. Abstracts: 10

52. Abstracts: 10

53. Abstracts: 10

54. Abstracts: 10

55. Abstracts: 10

56. Abstracts: 10

57. Abstracts: 10

58. Abstracts: 10

59. Abstracts: 10

60. Abstracts: 10

61. Abstracts: 10

62. Abstracts: 10

63. Abstracts: 10

64. Abstracts: 10

65. Abstracts: 10

66. Abstracts: 10

67. Abstracts: 10

68. Abstracts: 10

69. Abstracts: 10

70. Abstracts: 10

71. Abstracts: 10

72. Abstracts: 10

73. Abstracts: 10

74. Abstracts: 10

75. Abstracts: 10

76. Abstracts: 10

77. Abstracts: 10

78. Abstracts: 10

79. Abstracts: 10

80. Abstracts: 10

81. Abstracts: 10

82. Abstracts: 10

83. Abstracts: 10

84. Abstracts: 10

85. Abstracts: 10

86. Abstracts: 10

87. Abstracts: 10

88. Abstracts: 10

89. Abstracts: 10

90. Abstracts: 10

91. Abstracts: 10

92. Abstracts: 10

93. Abstracts: 10

94. Abstracts: 10

95. Abstracts: 10

96. Abstracts: 10

97. Abstracts: 10

98. Abstracts: 10

99. Abstracts: 10

100. Abstracts: 10

101. Abstracts: 10

102. Abstracts: 10

103. Abstracts: 10

104. Abstracts: 10

105. Abstracts: 10

106. Abstracts: 10

107. Abstracts: 10

108. Abstracts: 10

109. Abstracts: 10

110. Abstracts: 10

111. Abstracts: 10

112. Abstracts: 10

113. Abstracts: 10

114. Abstracts: 10

115. Abstracts: 10

116. Abstracts: 10

117. Abstracts: 10

118. Abstracts: 10

119. Abstracts: 10

120. Abstracts: 10

121. Abstracts: 10

122. Abstracts: 10

123. Abstracts: 10

124. Abstracts: 10

125. Abstracts: 10

126. Abstracts: 10

127. Abstracts: 10

128. Abstracts: 10

129. Abstracts: 10

130. Abstracts: 10

131. Abstracts: 10

132. Abstracts: 10

133. Abstracts: 10

134. Abstracts: 10

135. Abstracts: 10

136. Abstracts: 10

137. Abstracts: 10

138. Abstracts: 10

139. Abstracts: 10

140. Abstracts: 10

141. Abstracts: 10

142. Abstracts: 10

143. Abstracts: 10

144. Abstracts: 10

145. Abstracts: 10

146. Abstracts: 10

147. Abstracts: 10

148. Abstracts: 10

149. Abstracts: 10

150. Abstracts: 10

151. Abstracts: 10

152. Abstracts: 10

153. Abstracts: 10

154. Abstracts: 10

155. Abstracts: 10

156. Abstracts: 10

157. Abstracts: 10

158. Abstracts: 10

159. Abstracts: 10

160. Abstracts: 10

161. Abstracts: 10

162. Abstracts: 10

163. Abstracts: 10

164. Abstracts: 10

165. Abstracts: 10

166. Abstracts: 10

167. Abstracts: 10

168. Abstracts: 10

169. Abstracts: 10

170. Abstracts: 10

171. Abstracts: 10

172. Abstracts: 10

173. Abstracts: 10

174. Abstracts: 10

175. Abstracts: 10

176. Abstracts: 10

177. Abstracts: 10

178. Abstracts: 10

179. Abstracts: 10

180. Abstracts: 10

181. Abstracts: 10

182. Abstracts: 10

183. Abstracts: 10

184. Abstracts: 10

185. Abstracts: 10

186. Abstracts: 10

187. Abstracts: 10

188. Abstracts: 10

189. Abstracts: 10

190. Abstracts: 10

191. Abstracts: 10

192. Abstracts: 10

193. Abstracts: 10

194. Abstracts: 10

195. Abstracts: 10

196. Abstracts: 10

197. Abstracts: 10

198. Abstracts: 10

199. Abstracts: 10

200. Abstracts: 10

201. Abstracts: 10

202. Abstracts: 10

203. Abstracts: 10

204. Abstracts: 10

205. Abstracts: 10

206. Abstracts:</

[illegible]

Natural History

- **Catcratch** (JUL 2010)
 - Treated (cat) and untreated (dog) to 18° students
 - T10 untreated group had lymphoma
 - Resected adenocarcinoma in programmed CT for
 - All dogs T10 for lymphoma and 8° to lymphoma
- **Molecular Spike (2011)**
 - Vastly different adenocarcinoma and lymphoma
 - Adenocarcinoma programs between the two
 - Lymphoma programs after adenocarcinoma



Rapid progression 5 to 60 degrees

University of Birmingham
School of Medicine

Radiographic characteristics of dysphrolic osteolisis

- Certain radiographic characteristics have been recognized in specific dysphrolic osteolisis
- Radiographic characteristics are not always specific and may be variable
- Radiographic features must be interpreted according to the anamnesis
- Careful evaluation of these radiographic features may indicate the type and the timing of treatment in specific dysphrolic osteolisis and determine the prognosis

Table 1. XRD Radiographic Characteristics of Dysphrolic Osteolisis in TMJ

	Prevalence
Arthralgia	100%
Condylar erosion	90%
Unilateral condylar collapse	70%
Condylar resorption	60%
Spontaneous condylar necrosis	20%
Anterior condylar dislocation	20%
Unilateral ankylosed TMJ	20%
Unilateral ankylosed TMJ	20%
Unilateral ankylosed TMJ	20%
Unilateral ankylosed TMJ	20%

From Okada et al. *Journal of Oral Rehabilitation* 31: 200-204, 2004

Identification of specific radiographic features may indicate the type and the timing of treatment in specific dysphrolic osteolisis and determine the prognosis



Developed by Dr. Mauricio
de Souza

Objective

The purpose of this study is to assess the inter-observer reliability of 8 radiographic characteristics of dystrophic modulation in NF1.

Materials and Methods

- Multicenter contribution
- 122 sites (AP & Lat) of patient studies with NPT
- 6 vertebrae measured by 5 spine surgeons
- 8 Radiographic characteristics (sympathetic recesses) →
- related to final diagnosis
- inter-observer reliability was performed using Fleiss' kappa.
- Vertebral wedging
- Vertebral rotation
- Sharp angular curve
- Rib penciling
- Vertebral scalloping
- Widened interpedicular distance
- Atypical location
- Spindling of transverse processes

Inter-observer	
Of the 122 cases, 83(68%) were dystrophic and 39(32%) were non-dystrophic.	
Overall agreement for dystrophic diagnosis was 0.61(good).	

Results

- For dystrophic diagnosis
 - all 5 readers agreed that a case was dystrophic in 46 of 122 cases, and non-dystrophic in 30 of 122 cases.
 - but there was some disagreement in 46 cases.
- For wedding, where the agreement was 'good', the readers completely agreed more than half of the time.
- In contrast, where the agreement was 'poor', the readers disagreed in nearly all the cases.



University of Birmingham
School of Management

Variable Item	Rate observed in all 800 readings	Rate observed in only 400 readings (Dysmorphia)	Rate observed in only 200 readings (Dysmorphia)
Relative weighting	41.2 %	70.0 %	50.0 %
Relative rotation	41.2	70.1	50.3
They angular curve	53.0	60.2	29.2
Fit packing	42.8	54.4	18.0
Relative weighting	40.7	48.8	27.7
Relative interparticle distance	36.1	43.0	18.0
Angular location	22.3	39.6	6.7
Handling of interarea particles	10.1	18.3	6.3

Discussion: Dystrophic Modulation

- Durani et al, Spine 2000
 - Modulation occurred 65% of patients
 - Modulation occurred in 51% of patients scoliosis presented before 7 years and 25% after 7 years
 - Rib penciling only factor influenced progression
 - Progression rate: scoliosis 12" and kyphosis 5"
- Dystrophic modulation may explain underestimation of dystrophic diagnosis by 5 raters.

Summary

- Overall dystrophic diagnosis can be reliably assessed by radiographic characteristics.
- Some radiographic characteristics, such as wedging, can be reliably assessed with good agreement.
- The agreement on other characteristics, such as scalloping, is poor.

[illegible]

Abstract #2

**Neurofibromatosis type 1 and Dystrophic
Scoliosis: A Multicenter Study of
Accuracy of Surgeons' Radiographic
Assessment**

Ledonio, Charles; Gennarelli, T. P.; Polley, David W. J.
Renshaw, Ann M.; Lachy, A.; Fowler, Scott; Davies, J. P.
Campbell, Leslie T. P.; Crawford, Anne M.; Rosenbaum, David
A. P.; Vitek, William J. P.; Muehle, Christopher J. P.

- 1. University of Minnesota, Minneapolis, MN, United States
- 2. University of Minnesota, Minneapolis, MN, United States
- 3. Texas Southern University, Houston, Texas, United States
- 4. University of Minnesota, Minneapolis, MN, United States
- 5. Mayo Clinic, Rochester, MN, United States
- 6. University of Minnesota, Minneapolis, MN, United States
- 7. University of Minnesota, Minneapolis, MN, United States

 University of Minnesota

[illegible]

**Scoliosis In Neurofibromatosis type1:
Dystrophic or non-dystrophic**

- Nondystrophic and dystrophic
- Most common osseous defect
- 2% of pts with scoliosis will have NF-1
- 30% of patients with NF-1 have spine disorders
- Dystrophic more severe

SOS - Prevalence of scoliosis in NF1			
Study	Number	Prevalence	Age
Strandberg (1980)	40%		
Strandberg (1982)			
Strandberg (1983)	30%	14%	
Strandberg (1985)	0.6%		
Strandberg (1986)	0.2%		
Strandberg (1987)	0.2%		
Strandberg (1988)	0.2%		
Strandberg (1989)	0.2%		
Strandberg (1990)	0.2%		
Strandberg (1991)	0.2%		
Strandberg (1992)	0.2%		
Strandberg (1993)	0.2%		
Strandberg (1994)	0.2%		
Strandberg (1995)	0.2%		
Strandberg (1996)	0.2%		
Strandberg (1997)	0.2%		
Strandberg (1998)	0.2%		
Strandberg (1999)	0.2%		
Strandberg (2000)	0.2%		
Strandberg (2001)	0.2%		
Strandberg (2002)	0.2%		
Strandberg (2003)	0.2%		
Strandberg (2004)	0.2%		
Strandberg (2005)	0.2%		
Strandberg (2006)	0.2%		
Strandberg (2007)	0.2%		
Strandberg (2008)	0.2%		
Strandberg (2009)	0.2%		
Strandberg (2010)	0.2%		
Strandberg (2011)	0.2%		
Strandberg (2012)	0.2%		
Strandberg (2013)	0.2%		
Strandberg (2014)	0.2%		
Strandberg (2015)	0.2%		
Strandberg (2016)	0.2%		
Strandberg (2017)	0.2%		
Strandberg (2018)	0.2%		
Strandberg (2019)	0.2%		
Strandberg (2020)	0.2%		
Strandberg (2021)	0.2%		
Strandberg (2022)	0.2%		
Strandberg (2023)	0.2%		
Strandberg (2024)	0.2%		
Strandberg (2025)	0.2%		
Strandberg (2026)	0.2%		
Strandberg (2027)	0.2%		
Strandberg (2028)	0.2%		
Strandberg (2029)	0.2%		
Strandberg (2030)	0.2%		
Strandberg (2031)	0.2%		
Strandberg (2032)	0.2%		
Strandberg (2033)	0.2%		
Strandberg (2034)	0.2%		
Strandberg (2035)	0.2%		
Strandberg (2036)	0.2%		
Strandberg (2037)	0.2%		
Strandberg (2038)	0.2%		
Strandberg (2039)	0.2%		
Strandberg (2040)	0.2%		
Strandberg (2041)	0.2%		
Strandberg (2042)	0.2%		
Strandberg (2043)	0.2%		
Strandberg (2044)	0.2%		
Strandberg (2045)	0.2%		
Strandberg (2046)	0.2%		
Strandberg (2047)	0.2%		
Strandberg (2048)	0.2%		
Strandberg (2049)	0.2%		
Strandberg (2050)	0.2%		
Strandberg (2051)	0.2%		
Strandberg (2052)	0.2%		
Strandberg (2053)	0.2%		
Strandberg (2054)	0.2%		
Strandberg (2055)	0.2%		
Strandberg (2056)	0.2%		
Strandberg (2057)	0.2%		
Strandberg (2058)	0.2%		
Strandberg (2059)	0.2%		
Strandberg (2060)	0.2%		
Strandberg (2061)	0.2%		
Strandberg (2062)	0.2%		
Strandberg (2063)	0.2%		
Strandberg (2064)	0.2%		
Strandberg (2065)	0.2%		
Strandberg (2066)	0.2%		
Strandberg (2067)	0.2%		
Strandberg (2068)	0.2%		
Strandberg (2069)	0.2%		
Strandberg (2070)	0.2%		
Strandberg (2071)	0.2%		
Strandberg (2072)	0.2%		
Strandberg (2073)	0.2%		
Strandberg (2074)	0.2%		
Strandberg (2075)	0.2%		
Strandberg (2076)	0.2%		
Strandberg (2077)	0.2%		
Strandberg (2078)	0.2%		
Strandberg (2079)	0.		

Natural History

- Catalani et al. JGIM 1992
 - Treated (n=12) vs. untreated (n=22) w/ HF patients
 - 75% untreated group had hypertension
 - Seven patients undergoing progressive HF
 - All others 7+ yr progression and 6% of patients
- Wolfe et al. Spine 1994
 - Vertebral osteolysis, the winging appearance
 - Acute fracture, progressive destruction
 - Progressive deformity
 - Progression after steroids



rapid progression 5 to 10 days


**Radiographie characteristics of
dysrophic soilcicle**


- Certain radiographic characteristics have been reported to predict dysrophic soilcicles, but their predictive value is not well described.

Table 1. XRD BACKGROUND CHARACTERISTICS OF DYSOPHIC SOILCICLES IN NIA

Characteristics	% incidence
Amorphous	42
Unidist crystals	3
Sparsely oriented soilcicles	4
Unidist soilcicles	4
Isolated characteristic soilcicles	3
Sparsely oriented soilcicles	3
Isolated uncharacteristic soilcicles	3
Isolated uncharacteristic biomass	2
Isolated oriented soilcicles	1

From: Korman et al. *Journal of Soil Health*, 30, 99-104.
 Detection of plant alterations in green tea.
Phytopathologia 91, 1 (Jan. 2002) 24-37.





Objective

This study aims to determine the accuracy of radiographic assessment of dystrophic modulation in NF1 patients with scoliosis.

[illegible]

Results

- The actual diagnosis was dystrophic for 83 of the 122 x-rays, or 68% and 39(32%) were non-dystrophic
- Readers underestimated the proportion that were dystrophic.

Reader	Frequency Non-dystrophic	Frequency Dystrophic
1	17 (14%)	65 (53%)
2	40 (33%)	77 (63%)
3	45 (37%)	62 (51%)
4	48 (39%)	71 (58%)
5	67 (55%)	55 (45%)
Total	217 (178%)	363 (298%)

Results			
• Dystrophic scoliosis: Sensitivity of 75% (310/415 reads)			
• Non-dystrophic: Specificity of 73% (142/195 reads).			
• Positive predictive value = 85%.			
• Negative predictive value = 57%.			

Results

- All 6 characteristics are strongly associated with dystrophic scales ($p < 0.0001$).
- The association is strongest for atypical location (90–94%) and weak, (yet significant) for scaling (90–94%).

Characteristic	Sensitivity	Specificity	Relative AOR ^a [95% CI]
Atypical location	75.3	72.0	1.46 (1.28–1.65)
Weak scaling	75.3	49.2	1.47 (1.19–1.87)
Large scale type	80.3	76.9	1.38 (1.22–1.54)
Large scale size	80.3	76.9	1.38 (1.22–1.54)
Scaling	90.3	94.3	1.21 (1.03–1.41)
Shedding substrate	46.0	75.3	1.39 (1.13–1.71)
Shedding substrate distance	46.0	80.5	1.24 (1.04–1.46)
Aggregation	70.3	76.9	1.44 (1.22–1.69)
Scaling & transmembrane	70.3	76.9	1.27 (1.04–1.57)

^a Odds of a scale being the indicated characteristic, relative to scales that are not the indicated characteristic.

Discussion: Dystrophic Modulation

- *Dumari et al, Spine 2000*
 - Modulation occurred 65% of patients
 - Modulation occurred in 51% of patients scoliosis presented before 7 years and 25% after 7 years
 - Rib penciling: only factor influenced progression
 - Progression rate: scoliosis 12° and kyphosis 8°
- Dystrophic modulation may explain underestimation of dystrophic diagnosis by 5 raters.

Summary

- The 8 radiographic characteristics were significantly associated with dystrophic modulation in NF1 patients with scoliosis.
- Wedging and rotation were most sensitive, atypical location and transverse processes spindling were most specific.
- On balance, atypical location and rib penciling had the strongest association with dystrophic scoliosis.

[illegible]

Abstract #3

Neurofibromatosis Type I and Scoliosis: A Multicenter Study to Determine Radiographic Predictors of Dystrophic Scoliosis

1. University of Illinois, Urbana-Champaign, IL, United States
2. General Electric, Natick, MA, United States
3. Texas A&M University, Houston, TX, United States
4. Center for Polymer and Surface Science, University of Illinois, Urbana-Champaign, IL, United States
5. Texas A&M University, Houston, TX, United States
6. University of Illinois, Urbana-Champaign, IL, United States
7. Columbia University, New York, NY, United States



E-Poster # 545: NF1 & Scoliosis: Multicenter Radiographic Predictors
 Presenter: Charles T. Leckner, MD, University of Michigan, Ann Arbor, MI 48106-0000

<ul style="list-style-type: none"> • Chlorophyll a (blue-green, 430 nm) • Chlorophyll b (yellow-green, 453 nm) • Carotenoids (yellow-orange, 480 nm) • Xanthophylls (yellow, 490 nm) • Lutein (yellow, 495 nm) • Violaxanthin (yellow, 500 nm) • Zeaxanthin (orange-red, 515 nm) • Peridinin (red, 520 nm) • Alloxanthin (red, 530 nm) • Chlorophyll d (red, 550 nm) • Chlorophyll e (red, 560 nm) • Chlorophyll f (red, 570 nm) • Chlorophyll g (red, 580 nm) • Chlorophyll h (red, 590 nm) • Chlorophyll i (red, 600 nm) • Chlorophyll j (red, 610 nm) • Chlorophyll k (red, 620 nm) • Chlorophyll l (red, 630 nm) • Chlorophyll m (red, 640 nm) • Chlorophyll n (red, 650 nm) • Chlorophyll o (red, 660 nm) • Chlorophyll p (red, 670 nm) • Chlorophyll q (red, 680 nm) • Chlorophyll r (red, 690 nm) • Chlorophyll s (red, 700 nm) • Chlorophyll t (red, 710 nm) • Chlorophyll u (red, 720 nm) • Chlorophyll v (red, 730 nm) • Chlorophyll w (red, 740 nm) • Chlorophyll x (red, 750 nm) • Chlorophyll y (red, 760 nm) • Chlorophyll z (red, 770 nm) • Chlorophyll aa (red, 780 nm) • Chlorophyll ab (red, 790 nm) • Chlorophyll ac (red, 800 nm) • Chlorophyll ad (red, 810 nm) • Chlorophyll ae (red, 820 nm) • Chlorophyll af (red, 830 nm) • Chlorophyll ag (red, 840 nm) • Chlorophyll ah (red, 850 nm) • Chlorophyll ai (red, 860 nm) • Chlorophyll aj (red, 870 nm) • Chlorophyll ak (red, 880 nm) • Chlorophyll al (red, 890 nm) • Chlorophyll am (red, 900 nm) • Chlorophyll an (red, 910 nm) • Chlorophyll ao (red, 920 nm) • Chlorophyll ap (red, 930 nm) • Chlorophyll aq (red, 940 nm) • Chlorophyll ar (red, 950 nm) • Chlorophyll as (red, 960 nm) • Chlorophyll at (red, 970 nm) • Chlorophyll au (red, 980 nm) • Chlorophyll av (red, 990 nm) • Chlorophyll aw (red, 1000 nm) • Chlorophyll ax (red, 1010 nm) • Chlorophyll ay (red, 1020 nm) • Chlorophyll az (red, 1030 nm) • Chlorophyll ba (red, 1040 nm) • Chlorophyll bb (red, 1050 nm) • Chlorophyll bc (red, 1060 nm) • Chlorophyll bd (red, 1070 nm) • Chlorophyll be (red, 1080 nm) • Chlorophyll bf (red, 1090 nm) • Chlorophyll bg (red, 1100 nm) • Chlorophyll bh (red, 1110 nm) • Chlorophyll bi (red, 1120 nm) • Chlorophyll bj (red, 1130 nm) • Chlorophyll bk (red, 1140 nm) • Chlorophyll bl (red, 1150 nm) • Chlorophyll bm (red, 1160 nm) • Chlorophyll bn (red, 1170 nm) • Chlorophyll bo (red, 1180 nm) • Chlorophyll bp (red, 1190 nm) • Chlorophyll bq (red, 1200 nm) • Chlorophyll br (red, 1210 nm) • Chlorophyll bs (red, 1220 nm) • Chlorophyll bt (red, 1230 nm) • Chlorophyll bu (red, 1240 nm) • Chlorophyll bv (red, 1250 nm) • Chlorophyll bw (red, 1260 nm) • Chlorophyll bx (red, 1270 nm) • Chlorophyll by (red, 1280 nm) • Chlorophyll bz (red, 1290 nm) • Chlorophyll ca (red, 1300 nm) • Chlorophyll cb (red, 1310 nm) • Chlorophyll cc (red, 1320 nm) • Chlorophyll cd (red, 1330 nm) • Chlorophyll ce (red, 1340 nm) • Chlorophyll cf (red, 1350 nm) • Chlorophyll cg (red, 1360 nm) • Chlorophyll ch (red, 1370 nm) • Chlorophyll ci (red, 1380 nm) • Chlorophyll cj (red, 1390 nm) • Chlorophyll ck (red, 1400 nm) • Chlorophyll cl (red, 1410 nm) • Chlorophyll cm (red, 1420 nm) • Chlorophyll cn (red, 1430 nm) • Chlorophyll co (red, 1440 nm) • Chlorophyll cp (red, 1450 nm) • Chlorophyll cq (red, 1460 nm) • Chlorophyll cr (red, 1470 nm) • Chlorophyll cs (red, 1480 nm) • Chlorophyll ct (red, 1490 nm) • Chlorophyll cu (red, 1500 nm) • Chlorophyll cv (red, 1510 nm) • Chlorophyll cw (red, 1520 nm) • Chlorophyll cx (red, 1530 nm) • Chlorophyll cy (red, 1540 nm) • Chlorophyll cz (red, 1550 nm) • Chlorophyll da (red, 1560 nm) • Chlorophyll db (red, 1570 nm) • Chlorophyll dc (red, 1580 nm) • Chlorophyll dd (red, 1590 nm) • Chlorophyll de (red, 1600 nm) • Chlorophyll df (red, 1610 nm) • Chlorophyll dg (red, 1620 nm) • Chlorophyll dh (red, 1630 nm) • Chlorophyll di (red, 1640 nm) • Chlorophyll dj (red, 1650 nm) • Chlorophyll dk (red, 1660 nm) • Chlorophyll dl (red, 1670 nm) • Chlorophyll dm (red, 1680 nm) • Chlorophyll dn (red, 1690 nm) • Chlorophyll do (red, 1700 nm) • Chlorophyll dp (red, 1710 nm) • Chlorophyll dq (red, 1720 nm) • Chlorophyll dr (red, 1730 nm) • Chlorophyll ds (red, 1740 nm) • Chlorophyll dt (red, 1750 nm) • Chlorophyll du (red, 1760 nm) • Chlorophyll dv (red, 1770 nm) • Chlorophyll dw (red, 1780 nm) • Chlorophyll dx (red, 1790 nm) • Chlorophyll dy (red, 1800 nm) • Chlorophyll dz (red, 1810 nm) • Chlorophyll ea (red, 1820 nm) • Chlorophyll eb (red, 1830 nm) • Chlorophyll ec (red, 1840 nm) • Chlorophyll ed (red, 1850 nm) • Chlorophyll ee (red, 1860 nm) • Chlorophyll ef (red, 1870 nm) • Chlorophyll eg (red, 1880 nm) • Chlorophyll eh (red, 1890 nm) • Chlorophyll ei (red, 1900 nm) • Chlorophyll ej (red, 1910 nm) • Chlorophyll ek (red, 1920 nm) • Chlorophyll el (red, 1930 nm) • Chlorophyll em (red, 1940 nm) • Chlorophyll en (red, 1950 nm) • Chlorophyll eo (red, 1960 nm) • Chlorophyll ep (red, 1970 nm) • Chlorophyll eq (red, 1980 nm) • Chlorophyll er
--


Scoliosis in Neurofibromatosis type1: Dystrophic or non-dystrophic

- | | L19 / Zetterstrom et al 95 | | Etiology |
|--|----------------------------|----------|----------|
| | Number | Survival | |
| Nondegenerative and dysplastic | | | |
| Most common osseous defect | | | |
| 2% of pts with scoliosis will have NF-1 | | | |
| 30% of patients with NF-1 have apine disorders | | | |
| Dysplastic more severe | | | |
- Standard ICDM 2007

Year	Median Age (years)	Female Percentage	Male Percentage
1990-1991	45	50	50
1992-1993	45	50	50
1994-1995	45	50	50
1996-1997	45	50	50
1998-1999	45	50	50
2000-2001	45	50	50
2002-2003	45	50	50
2004-2005	45	50	50
2006-2007	45	50	50
2008-2009	45	50	50
2010-2011	45	50	50
2012-2013	45	50	50
2014-2015	45	50	50
2016-2017	45	50	50
2018-2019	45	50	50
2020-2021	45	50	50

Natural History

- Calvert et al. JGIM 1995
 - Treated (n=24) and untreated (n=22) w/ MPV infection
 - 73% untreated group had hepatomegaly
 - Review criteria outlining a "programmed CD" dx
 - All others "Ac progression and B" dx of Hepoma
- Williams et al. Spine 1994
 - Vertebral osteomyelitis, discitis and epidural abscess
 - Initial diagnosis: pyogenic infection that produces progression after antibiotic



Radiographic characteristics of dystrophic colitis

- [illegible]

Observations	% subjects
Unformed tissue	<1
Formed epithelial scaling	75
Formed rete ridges	75
Spreading keratinized granules	75
Adhesive epithelial granules	25
Unfixed epithelial granules	25
Unfixed epithelial granules	25
Unfixed epithelial granules	25
Unfixed epithelial granules	25



Figure 1. Micrograph showing epithelial granules.

Objective

This study aims to determine which combination of x-ray characteristics was best able to predict true dystrophic status.

Materials and Methods

- [illegible]

Results

- The actual diagnosis was dystrophic for 83 of the 122 x-rays, or 68% and 39(32%) were non-dystrophic
- Readers underestimated the proportions that were dystrophic.

Gender	Frequency (Absolute Number)	Frequency (Percentage)
1	37 (33%)	37 (31%)
2	42 (37%)	77 (63%)
3	40 (35%)	40 (33%)
4	48 (42%)	74 (60%)
5	47 (41%)	50 (40%)
Total	247 (17%)	383 (58%)

Logistic regression analysis: modeling backward, forward and stepwise elimination

- Spindling of transverse process
- Short sharp angular curve
- Widened interpedicular space
- Vertebral scalloping
- $p < 0.05$

- Rib penolling
- Vertebral rotation
- Vertebral wedging
- Atypical location
- $p < 0.05$

Results

- The odds of an x-ray being dystrophic were 2.43 times higher when rib penciling was present; vertebral rotation - 2.90; vertebral wedging - 2.37; & atypical location 5.00
- If all 4 characteristics patterns were present there would be a 51 times higher risk of dystrophic curve pattern.

Table 1. Odds ratios of radiographic characteristics

Characteristic	Odds Ratio (95% CI)
Vertical rotation	2.58 (1.85 – 4.79)
Vertical wedging	2.47 (1.47 – 4.12)
Slit pencil	2.43 (1.51 – 4.12)
Angular location	5.00 (3.57 – 6.97)

Model summary

- The model predicts that the probability of an x-ray being truly dystrophic is about 31% if the reader saw none of these four characteristics.
- The probability rises to about 52-58% if the reader saw one of the four characteristics, to about 72-80% if he saw two of them, to about 85-91% if he saw three of them, and to about 98% if he saw all four of them.

Conclusion

- Only four of the 8 classic radiographic findings of dystrophic scoliosis are most predictive.
 - Rib penciling
 - Vertebral rotation
 - Vertebral wedging
 - Atypical curve location
- Further research to predict dystrophic curve patterns should focus on these radiographic markers.


Thank you

[illegible]

SUPPORTING DATA:

Please see body.

NO COST EXTENSION APPROVAL DOCUMENTS:

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT			1. CONTRACT ID CODE S	PAGE OF PAGES 1 9
2. AMENDMENT/MODIFICATION NO. P00001	3. EFFECTIVE DATE 31-Jul-2013	4. REQUISITION PURCHASE REQ. NO. W81XWH-10-1-0489	5. PROJECT NO. (If applicable)	
6. ISSUED BY US ARMY MEDICAL RESEARCH ACQUISITION ACT DIRECTOR 820 CHANDLER STREET FORT DETRICK MD 21702-5014	CODE W81XWH	7. ADMINISTERED BY (If other than item 6) US ARMY MEDICAL RESEARCH ACQUISITION ACT ATTN: CHASEN DEBNER 301-819-8585 CHASEN.DEBNER.CIV@MAIL.MIL FORT DETRICK MD 21702		
8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) REGENTS OF THE UNIVERSITY OF MINNESOTA OFFICE OF SPONSORED PROJECTS 200 OAK STREET SE MINNEAPOLIS MN 55455-2009			9A. AMENDMENT OF SOLICITATION NO.	
			9B. DATED (SEE ITEM 11)	
			X 10A. MOD. OF CONTRACT/ORDER NO. W81XWH-10-1-0489	
			X 10B. DATED (SEE ITEM 13) 01-Aug-2010	
CODE 0DH95		FACILITY CODE		
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS				
<input type="checkbox"/> The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of offers <input type="checkbox"/> is extended, <input type="checkbox"/> is not extended.				
Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If, in view of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.				
12. ACCOUNTING AND APPROPRIATION DATA (If required)				
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.				
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.				
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).				
X C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: Federal Demonstration Partnership, Phase V, dated July 1, 2008				
D. OTHER (Specify type of modification and authority)				
E. IMPORTANT: Contractor <input checked="" type="checkbox"/> is not, <input type="checkbox"/> is required to sign this document and return _____ copies to the issuing office.				
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Modification Control Number: cdeener135321 This modification extends the period of performance of the grant by 12 months at no additional cost to the agreement per the recipient's request dated 25 July 2013. An annual technical reports shall be submitted no later than 31 August 2013 and the final report is due by 31 August 2014. Quarterly submissions of the SF 425 shall continue during the no-cost extension period. The next quarterly SF 425 shall be submitted no later than 31 October 2013. Administrative changes have been made as well. See the Summary of Changes. Pt David Polly Title: Genetic Evaluation for the Scoliosis Gene(s) in Patients with Neurofibromatosis 1 and Scoliosis Period of Performance: 01 August 2010- 31 August 2014 (research ends 31 July 2014) Award Amount: \$705,183 Obligated Amount: \$705,183				
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.				
15A. NAME AND TITLE OF SIGNER (Type or print)		16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) WENDY A. BAKER / CONTRACTING OFFICER TEL: 301-819-2034 EMAIL: wendy.baker.civ@mail.mil		
15B. CONTRACTOR/OFFEROR (Signature of person authorized to sign)	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA BY  (Signature of Contracting Officer)	16C. DATE SIGNED 31-Jul-2013	

EXCEPTION TO SF 30
APPROVED BY OIRM 11-84

30-105-04

STANDARD FORM 30 (Rev. 10-83)
Prescribed by GSA
FAR (48 CFR) 53.243

SECTION SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES

SECTION 00010 - SOLICITATION CONTRACT FORM

The discount terms has changed from net 7 days to Net 7 Days.

The 'administered by' organization has changed from

USA MED RESEARCH ACQ ACTIVITY

ATTN: JASON KUHNS

301-619-1861

JASON.KUHNS1@US.ARMY.MIL

FORT DETRICK MD 21702

to

US ARMY MEDICAL RESEARCH ACQUISITION ACT

ATTN: CHASEN DEENER

301-619-8585

CHASEN.N.DEENER.CIV@MAIL.MIL

FORT DETRICK MD 21702

CLIN 0001

The CLIN extended description has changed from Period of Performance: 01 August 2010- 31 August 2013 (research ends 31 July 2013) to Period of Performance: 01 August 2010- 31 August 2014 (research ends 31 July 2014).

DELIVERIES AND PERFORMANCE

The following Delivery Schedule item for CLIN 0001 has been changed from:

DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	UIC
---------------	----------	-----------------	-----

POP 01-AUG-2010 TO

31-AUG-2013 N/A USA MED RESEARCH MAT CMD

1077 PATCHEL STREET

BLDG 1056

FORT DETRICK MD 21702

FOB: Destination W91ZSQ

To:

DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	UIC
---------------	----------	-----------------	-----

POP 01-AUG-2010 TO

31-AUG-2014 N/A USA MED RESEARCH MAT CMD

1077 PATCHEL STREET

BLDG 1056

FORT DETRICK MD 21702
FOB: Destination W91ZSQ

SECTION 00800 - SPECIAL CONTRACT REQUIREMENTS

The following have been modified:

A. This award is made under the authority of 31 U.S.C. 6304 and 10 U.S.C. 2358. The recipient's statement of work and the revised budget, dated 15 July 2010, for this proposal submitted in response to the Fiscal Year 2009 (FY09) Department of Defense Neurofibromatosis Research Program Investigator Initiated Research Award Announcement, which closed 14 April 2009, are incorporated herein by reference. The Catalog of Federal Domestic Assistance Number relative to this award is CFDA 12.420.

B. ACCEPTANCE OF AWARD. The recipient is not required to countersign this assistance award. In case of disagreement, the recipient shall notify the Grants Officer and not assess the award any costs until such disagreement(s) is resolved.

C. MAXIMUM OBLIGATION (SEP 2006) (USAMRAA)

The maximum obligation for support of the project will not exceed the amount specified in the award, as amended. USAMRAA does not amend assistance agreements to provide additional funds for such purposes as reimbursement for unrecovered indirect costs resulting from the establishment of final negotiated rates or for increases in salaries, fringe benefits and other costs.

D. TERMS AND CONDITIONS: The recipient agrees to the General Terms and Conditions of the Federal Demonstration Partnership, Phase V, dated July 1, 2008 and Department of Army – Agency Specific Requirements. Modifications to the General Terms and Conditions dated July 1, 2008 are modified as indicated below.

1. PATENTS AND INVENTIONS (DEC 2001) (USAMRAA)

a. The recipient shall use the Interagency Edison through the National Institutes of Health Commons (<http://www.iedison.gov/>) for filing of Patent Application and Invention Disclosure. Negative reports are required and shall be submitted on a DD Form 882 to the Grants Officer. (DD Form 882 can be located on web site <http://www.usamraa.army.mil>).

b. Invention reports are due annually and at the end of the period of the award. Annual reports are due 30 days after the anniversary date of the award and final reports are due 30 days after the expiration of the award. The award will NOT be closed out until all invention reporting requirements are met.

2. TECHNICAL REPORTING REQUIREMENTS (DEC 2008) (USAMRAA)

Format Requirements for Annual/Final Reports

a. Annual reports must provide a complete summary of the research accomplishments to date with respect to the approved Statement of Work. Journal articles can be substituted for detailed descriptions of specific aspects of the research, but the original articles must be attached to the report as an appendix and appropriately

referenced in the text. The importance of the report to decisions relating to continued support of the research can not be over-emphasized. An annual report shall be submitted within 30 calendar days of the anniversary date of the award for the preceding 12 month period. If the award period of performance is extended by the Grants Officer, then an annual report must still be submitted within 30 days of the anniversary date of the award. A final report will be due upon completion of the extended performance date that describes the entire research effort.

b. A final report summarizing the entire research effort, citing data in the annual reports and appended publications shall be submitted at the end of the award performance period. The final report will provide a complete reporting of the research findings. Journal publications can be substituted for detailed descriptions of specific aspects of the research, but an original copy of each publication must be attached as an appendix and appropriately referenced in the text. All final reports must include a bibliography of all publications and meeting abstracts and a list of personnel (not salaries) receiving pay from the research effort.

Although there is no page limitation for the reports, each report shall be of sufficient length to provide a thorough description of the accomplishments with respect to the approved Statement of Work. Submission of the report in electronic format (PDF or Word file only), shall be submitted to <https://ers.amedd.army.mil>.

All reports shall have the following elements in this order

FRONT COVER: Sample front cover provided at https://mrmc.amedd.army.mil/index.cfm?pageid=researcher_resources.technical_reporting. The Accession Document (AD) Number should remain blank.

STANDARD FORM 298: Sample SF 298 provided at https://mrmc.amedd.army.mil/index.cfm?pageid=researcher_resources.technical_reporting. The abstract in Block 13 must state the purpose, scope, major findings and be an up-to-date report of the progress in terms of results and significance. Subject terms are keywords that may have previously assigned to the proposal abstract or are keywords that may be significant to the research. The number of pages shall include all pages that have printed data (including the front cover, SF 298, table of contents, and all appendices). Please count pages carefully to ensure legibility and that there are no missing pages as this delays processing of reports. Page numbers should be typed: please do not hand number pages.

TABLE OF CONTENTS: Sample table of contents provided at https://mrmc.amedd.army.mil/index.cfm?pageid=researcher_resources.technical_reporting.

INTRODUCTION: Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

BODY: This section of the report shall describe the research accomplishments associated with each task outlined in the approved Statement of Work. Data presentation shall be comprehensive in providing a complete record of the research findings for the period of the report. Provide data explaining the relationship of the most recent findings with that of previously reported findings. Appended publications and/or presentations may be substituted for detailed descriptions of methodology but must be referenced in the body of the report. If applicable, for each task outlined in the Statement of Work, reference appended publications and/or presentations for details of result findings and tables and/or figures. The report shall include negative as well as positive findings. Include problems in accomplishing any of the tasks. Statistical tests of significance shall be applied to all data whenever possible. Figures and graphs referenced in the text may be embedded in the text or appended. Figures and graphs can also be referenced in the text and appended to a publication. Recommended changes or future work to better address the research topic may also be included, although changes to the original Statement of Work must be approved by the Army Grants Officer's Representative. This approval must be obtained prior to initiating any change to the original Statement of Work.

KEY RESEARCH ACCOMPLISHMENTS: Bulleted list of key research accomplishments emanating from this research.

REPORTABLE OUTCOMES: Provide a list of reportable outcomes that have resulted from this research to include:

manuscripts, abstracts, presentations; patents and licenses applied for and/or issued; degrees obtained that are supported by this award; development of cell lines, tissue or serum repositories; informatics such as databases and animal models, etc.; funding applied for based on work supported by this award; employment or research opportunities applied for and/or received based on experience/training supported by this award.

CONCLUSION: Summarize the results to include the importance and/or implications of the completed research and when necessary, recommend changes on future work to better address the problem. A "so what section" which evaluates the knowledge as a scientific or medical product shall also be included in the conclusion of the report.

REFERENCES: List all references pertinent to the report using a standard journal format (i.e. format used in Science, Military Medicine, etc.).

APPENDICES: Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.

Pages shall be consecutively numbered throughout the report. **DO NOT RENUMBER PAGES IN THE APPENDICES.**

Mark all pages of the report which contain proprietary or unpublished data that should be protected by the U.S. Government. **REPORTS NOT PROPERLY MARKED FOR LIMITATION WILL BE DISTRIBUTED AS APPROVED FOR PUBLIC RELEASE.** It is the responsibility of the Principal Investigator to advise the U.S. Army Medical Research and Materiel Command when restricted limitation assigned to a document can be downgraded to Approved for Public Release. **DO NOT USE THE WORD "CONFIDENTIAL" WHEN MARKING DOCUMENTS.**

Manuscripts/Reprints, Abstracts

A copy of manuscripts or subsequent reprints resulting from the research shall be submitted to the USAMRMC. An extended abstract suitable for publication in the proceedings of the applicable research program is required in relation to a DOD meeting planned during the term of this award. The extended abstract shall (1) identify the accomplishments since award and (2) follow instructions to be prepared by the USAMRMC and promulgated at a later date. The extended abstract style will be dependent on the discipline.

3. PAYMENTS

ADVANCE PAYMENTS AND FULL FUNDING (DEC 2008) (USAMRAA)

a. Payments. Advance payments will be made to the recipient. Questions relative to payment issues involving Defense Finance and Accounting Service shall be directed to usarmy.detrick.medcom-usamraa.mbx.aa3@mail.mil.

b. Electronic Funds Transfer. All advance payments to the recipient will be made by electronic funds transfer (EFT). The recipient shall contact the Defense Finance and Accounting System (DFAS) named on the face page of this award to make arrangements for EFT. Failure to do so may result in nonpayment.

c. If the recipient fails to perform, the Grants Officer shall notify DFAS in writing to withhold payments.

d. Advance Payment Schedule

Year One \$240,988

Amount	On or About
\$60,247	01 August 2010
\$60,247	01 October 2010
\$60,247	01 January 2011
\$60,247	01 April 2011

Year Two \$239,385

Amount	On or About
\$59,846	01 July 2011
\$59,846	01 October 2011
\$59,846	01 January 2012
\$59,847	01 April 2012

Year Three \$224,810

Amount	On or About
\$56,202	01 July 2012
\$56,203	01 October 2012
\$56,202	01 January 2013
\$56,203	01 April 2013

e. Financial Reporting Requirements:

Federal Financial Report (SF 425): Quarterly and Final Reports (For reporting individual assistance agreements)

Reporting period end dates fall on the end of the calendar quarter for quarterly reports (3/31, 6/30, 9/30, 12/31) and the end date of the assistance agreement period of performance for the final report. Reports are due 30 days after the reporting period end date for quarterly reports and 90 days after the end date of the assistance agreement for the final report.

The SF425 and instructions for completion can be obtained from <https://usamraa.army.mil>. All SF425's shall be submitted electronically to usarmy.detrick.medcom-usamraa.mbx.sf425@mail.mil. The award number assigned

by USAMRAA, which looks similar to W81XWH-XX-X-XXXX shall be included in the subject line of the electronic submission.

NOTE: The SF425 is a single form that consolidates and replaces the Federal Cash Transaction Report (SF272.SF272A) and the Financial Status Report (SF269/SF269A)

f. Interest Bearing Account. Unless exempted by applicable Treasury-State agreements in accordance with the Cash Management Improvement Act (CMIA) (31 U.S.C. 3335), the recipient shall deposit all advance payments in an interest bearing account. Interest over the amount of \$250 per year shall be remitted annually to the Department of Health and Human Services, Payment Management System, P.O. Box 6021, Rockville, MD 20852. A copy of the transmittal letter stating the amount of interest remitted shall be sent to the U.S. Army Medical Research Acquisition Activity, ATTN: MCMR-AAA-AC, 820 Chandler Street, Fort Detrick, MD 21702-5014.

4. PROHIBITION OF USE OF HUMAN RESEARCH (JAN 2007) (USAMRAA)

**** PROHIBITION – READ FURTHER FOR DETAILS ****

Research under this award involving the use of human subjects, to include the use of human anatomical substances and/or human data, may not begin until the U.S. Army Medical Research and Materiel Command's Office of Research Protections, Human Research Protections Office (HRPO) approves the protocol. Written approval to begin research or subcontract for the use of human subjects under the applicable protocol proposed for this award will be issued from the US Army Medical Research and Materiel Command, HRPO, under separate letter to the recipient. A copy of this approval will be provided to the US Army Medical Research Acquisition Activity for the official file. Non-compliance with any provision of this clause may result in withholding of funds and or the termination of the award.

5. PROHIBITION OF USE OF LABORATORY ANIMALS (JAN 2007) (USAMRAA)

**** PROHIBITION – READ FURTHER FOR DETAILS ****

Notwithstanding any other provisions contained in this award or incorporated by reference herein, the recipient is expressly forbidden to use or subcontract for the use of laboratory animals in any manner whatsoever without the express written approval of the US Army Medical Research and Materiel Command, Animal Care and Use Office (ACURO). The recipient will receive written approval to begin research under the applicable protocol proposed for this award from the US Army Medical Research and Materiel Command, ACURO, under separate letter. A copy of this approval will be provided to the US Army Medical Research and Acquisition Activity for the official file. Non-compliance with any provision of this clause may result in the termination of the award.

6. PROHIBITION OF USE OF HUMAN CADAVERS (JAN 2007) (USAMRAA)

**** PROHIBITION – READ FURTHER FOR DETAILS****

Research under this award using human cadavers may not begin until the U.S. Army Medical Research and Materiel Command's Office of Research Protections, Human Research Protections Office (HRPO) approves the protocol. Written approval to begin research or subcontract for the use of human cadavers under the applicable protocol proposed for this award will be issued from the US Army Medical Research and Materiel Command, HRPO, under separate letter to the recipient. A copy of this approval will be provided to the US Army Medical Research Acquisition Activity for the official file. Non-compliance with any provision of this clause may result in withholding of funds and or the termination of the award.

7. SUPPORTING INFORMATION (APR 2008) (USAMRAA)

Information such as subawards, consultant agreements, vendor quotes, and personnel work agreements may be required in order to support proposed costs or to determine the employment status of personnel under the assistance agreement. The Government's receipt of this information does not constitute approval or acceptance of any term or condition included therein. The terms and conditions of the assistance agreement take precedence over any term or condition included in supporting information.

8. TRAFFICKING VICTIMS PROTECTION ACT (May 2008) (USAMRAA)

Trafficking in persons.

a. Provisions applicable to a recipient that is a private entity.

1. You as the recipient, your employees, subrecipients under this award, and subrecipients' employees may not--

i. Engage in severe forms of trafficking in persons during the period of time that the award is in effect;

ii. Procure a commercial sex act during the period of time that award is in effect; or

iii. Use forced labor in the performance of the award or subawards under the award.

2. We as the Federal awarding agency may unilaterally terminate this award, without penalty, if you or a subrecipient that is a private entity--

i. Is determined to have violated a prohibition in paragraph a.1 of this award term; or

ii. Has an employee who is determined by the agency official authorized to terminate the award to have violated a prohibition in paragraph a.1 of this award term through conduct that is either--

A. Associated with performance under this award; or

B. Imputed to you or the subrecipient using the standards and due process for imputing the conduct of an individual to an organization that are provided in 2 CFR 180, "OMB Guidelines to Agencies on Governmentwide Debarment and Suspension (Nonprocurement)," as implemented by our agency at 2 CFR part 1125.

b. Provision applicable to a recipient other than a private entity. We as the Federal awarding agency may unilaterally terminate this award, without penalty, if a subrecipient that is a private entity--

1. Is determined to have violated an applicable prohibition in paragraph a.1 of this award term; or

2. Has an employee who is determined by the agency official authorized to terminate the award to have violated an applicable prohibition in paragraph a.1 of this award term through conduct that is either--

i. Associated with performance under this award;

ii. Imputed to the subrecipient using the standards and due process for imputing the conduct of an individual to an organization that are provided in 2 CFR part 180, "OMB Guidelines to Agencies on Governmentwide Debarment and Suspension (Nonprocurement)," as implemented by our agency at 2 CFR part 1125.

c. Provision applicable to any recipient.

1. You must inform us immediately of any information you receive from any source alleging a violation of a prohibition in paragraph a.1 of the award term.

2. Our right to terminate unilaterally that is described in paragraph a.2. or b. of this section:

i. Implements section 106(g) of the Trafficking Victims Protection Act of 2000 (TVPA), as amended (22 U.S.C. 7104(g)), and

ii. Is in addition to all other remedies for noncompliance that are available to us under this award.

3. You must include the requirements of paragraph a.1 of this award term in any subaward you make to a private entity.

d. Definitions. For the purpose of this award term:

1. "Employee" means either:

i. An individual employed by you or a subrecipient who is engaged in the performance of the project or program under this award; or

ii. Another person engaged in the performance of the project or program under this award and not compensated by you including, but not limited to, a volunteer or individual whose services are contributed by a third party as an in-kind contribution toward cost sharing or matching requirements.

2. "Forced labor" means labor obtained by any of the following methods: the recruitment, harboring, transportation, provision, or obtaining of a person for labor or services, through the use of force, fraud, or coercion for the purpose of subjection to involuntary servitude, peonage, debt bondage, or slavery.

3. "Private entity":

i. Means any entity other than a State, local government, Indian Tribe, or foreign public entity, as those terms are defined in 2 CFR 175.25.

ii. Includes:

A. A nonprofit organization, including any nonprofit institution of higher education, hospital, or tribal organization other than one included in the definition of Indian Tribe at 2 CFR 175.25(b).

B. A for-profit organization.

4. "Severe forms of trafficking in persons," "commercial sex act," and "coercion" have the meanings given at section 103 of the TVPA, as amended (22 U.S.C. 7102).

(End of Summary of Changes)